Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  COVID-19

  Free Subscription


Articles published in Int J Infect Dis

Retrieve available abstracts of 584 articles:
HTML format



Single Articles


    October 2025
  1. OPPONG AE, Coelewij L, Hutchinson M, Carpenter B, et al
    Simple hyperinflammation scores predict mortality in hospitalised patients with COVID-19 and offer a personalised medicine approach to dexamethasone intervention.
    Int J Infect Dis. 2025 Oct 13:108119. doi: 10.1016/j.ijid.2025.108119.
    PubMed     Abstract available


  2. SONG JY, Choi WS, Heo JY, Kim YR, et al
    Safety and immunogenicity of a homologous booster dose of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: 12 months follow-up result of an open-label, non-randomised extension of a phase 1/2 trial.
    Int J Infect Dis. 2025 Oct 8:108108. doi: 10.1016/j.ijid.2025.108108.
    PubMed     Abstract available


  3. LI Y, Sun C, Zhao T, Ni Y, et al
    Etiology of Initial Treatment Failure in Non-immunosuppressed Adult Patients with Community-acquired Pneumonia.
    Int J Infect Dis. 2025 Oct 8:108110. doi: 10.1016/j.ijid.2025.108110.
    PubMed     Abstract available


  4. FARINAS RP, Alonso-Sardon M, Solis P, Alonso BR, et al
    The impact of the SARS-CoV-2 pandemic on the development of respiratory infections caused by Aspergillus spp., Mucor spp., and Pneumocystis jirovecii within the National Health System of Spain.
    Int J Infect Dis. 2025 Oct 7:108101. doi: 10.1016/j.ijid.2025.108101.
    PubMed     Abstract available


  5. KIM JA, Park S, Cho H, Jeong NY, et al
    Sex Differences in Adverse Event Reporting Rates Following COVID-19 Vaccination in South Korea During the Pandemic.
    Int J Infect Dis. 2025 Oct 6:108107. doi: 10.1016/j.ijid.2025.108107.
    PubMed     Abstract available


  6. WAN EYF, Choi MH, Wang B, Xu Y, et al
    Comparative Effectiveness of Combination Therapy with Nirmatrelvir-Ritonavir and Molnupiravir versus Monotherapy with Molnupiravir or Nirmatrelvir-Ritonavir in Hospitalised COVID-19 Patients: A Target Trial Emulation Study.
    Int J Infect Dis. 2025 Oct 3:108097. doi: 10.1016/j.ijid.2025.108097.
    PubMed     Abstract available


  7. QASEM DMAA, Esawy DAS, Asiri DIAAZ, Alasiri MFM, et al
    Case Report: Severe Neonatal Legionella pneumophila Pneumonia: Insights from Clinical Management and Epidemiological Investigation.
    Int J Infect Dis. 2025 Oct 1:108098. doi: 10.1016/j.ijid.2025.108098.
    PubMed     Abstract available


  8. PERROUD AP, Coronel DL, Rivas E
    Analyzing Seasonal Trends of Respiratory Syncytial Virus Circulation Using Latin American National Surveillance Database during Pre- and Post-COVID-19 Pandemic.
    Int J Infect Dis. 2025 Oct 1:108095. doi: 10.1016/j.ijid.2025.108095.
    PubMed     Abstract available


    September 2025
  9. KIM JM, Kim JA, Rhee JE, Kim EJ, et al
    Genomic surveillance for community-acquired pneumonia of unknown etiology in children.
    Int J Infect Dis. 2025 Sep 27:108093. doi: 10.1016/j.ijid.2025.108093.
    PubMed     Abstract available


  10. BONGUILI NCB, Mombo IM, Lenguiya LH, Lattaphasavang V, et al
    Etiology and Epidemiology of respiratory infections in community-based influenza-like illness during the COVID-19 pandemic, Vientiane, Lao People's Democratic Republic.
    Int J Infect Dis. 2025 Sep 25:108079. doi: 10.1016/j.ijid.2025.108079.
    PubMed     Abstract available


  11. TENG Z, Li L, Che T, Liang J, et al
    A Novel Balamuthia Lineage Causing Fatal Granulomatous Amoebic Encephalitis in an Immunocompetent Infant.
    Int J Infect Dis. 2025 Sep 17:108063. doi: 10.1016/j.ijid.2025.108063.
    PubMed     Abstract available


  12. PASQUINI Z, Toschi A, Gibertoni D, Amicucci A, et al
    Risk Factors for Persisting SARS-CoV-2 Infection in Patients with B-Cell Malignancies in the Omicron Era: A Multicenter Cohort Study.
    Int J Infect Dis. 2025 Sep 8:108053. doi: 10.1016/j.ijid.2025.108053.
    PubMed     Abstract available


  13. ROWE SL, Sullivan SG, Koerber JJ, Munoz FM, et al
    Adverse events associated with COVID-19 vaccination or diagnosis among pregnant and non-pregnant women in the United States, 2021-2022.
    Int J Infect Dis. 2025 Sep 5:108050. doi: 10.1016/j.ijid.2025.108050.
    PubMed     Abstract available


  14. SAGHAUG CS, Markussen DL, Knoop ST, Holvik BC, et al
    Diagnostic Accuracy of a Host Response Test in Suspected Community-Acquired Pneumonia During the COVID-19 Era.
    Int J Infect Dis. 2025 Sep 2:108045. doi: 10.1016/j.ijid.2025.108045.
    PubMed     Abstract available


  15. SIMONSEN L, Pedersen RK, Andreasen V, Krause TG, et al
    A Disease Suppression Strategy in Action: The Impact of Non-Pharmaceutical interventions in the COVID-19 pandemic in Denmark.
    Int J Infect Dis. 2025 Sep 2:108039. doi: 10.1016/j.ijid.2025.108039.
    PubMed     Abstract available


    August 2025
  16. SHANG L, Perniciaro S, Weinberger DM
    Changes in pneumococcal deaths in the United States following the COVID-19 pandemic.
    Int J Infect Dis. 2025 Aug 29:108020. doi: 10.1016/j.ijid.2025.108020.
    PubMed     Abstract available


  17. FERNANDEZ-DE-LAS-PENAS C, Ruiz-Ruigomez M, Esparcia-Pinedo L, Colom-Fernandez B, et al
    Classical Pathway Persistent Complement Activation is Associated with Specific Symptoms in Individuals with Post-COVID-19 Condition: A Case-Control Study.
    Int J Infect Dis. 2025 Aug 28:108032. doi: 10.1016/j.ijid.2025.108032.
    PubMed     Abstract available


  18. TENG O, Quek AML, Ooi DSQ, Wang S, et al
    High CD4(+) T-cell Responses in Seronegative Individuals Following SARS-CoV-2 Exposure during a Dormitory Outbreak.
    Int J Infect Dis. 2025 Aug 20:108024. doi: 10.1016/j.ijid.2025.108024.
    PubMed     Abstract available


  19. TURJEMAN A, Drozdinsky G, Leibovici L
    The Impact of the COVID-19 Pandemic on Influenza Vaccination: A Multi-Year Interrupted Time Series Analysis.
    Int J Infect Dis. 2025 Aug 11:108015. doi: 10.1016/j.ijid.2025.108015.
    PubMed     Abstract available


  20. CARAZO S, Ouakki M, Nicolakakis N, Falcone EL, et al
    Long COVID risk and severity after COVID-19 infections and reinfections: a retrospective cohort study among healthcare workers.
    Int J Infect Dis. 2025 Aug 7:108012. doi: 10.1016/j.ijid.2025.108012.
    PubMed     Abstract available


    July 2025
  21. DAVIDO B, Loubet P
    The Silent Surge: The Underrecognized Burden of Respiratory Syncytial Virus, Human Metapneumovirus, and Parainfluenza Viruses in Adults.
    Int J Infect Dis. 2025 Jul 31:108006. doi: 10.1016/j.ijid.2025.108006.
    PubMed     Abstract available


  22. MASI P, Lescroart M, Veinstein A, Desmedt L, et al
    Antifungal Concentrations in Mechanically Ventilated COVID-19 Patients With or Without ECMO: The CAPADOSE observational retrospective multicenter Study.
    Int J Infect Dis. 2025 Jul 25:107996. doi: 10.1016/j.ijid.2025.107996.
    PubMed     Abstract available


  23. ZHANG Y, Guo J, Li Y, Song Y, et al
    Pre-pregnancy vaccination with inactivated vaccines protects SARS-CoV-2-exposed neonates from respiratory distress.
    Int J Infect Dis. 2025 Jul 16:107978. doi: 10.1016/j.ijid.2025.107978.
    PubMed     Abstract available


  24. COBO-VAZQUEZ E, Aguilera-Alonso D, Grandioso-Vas D, Gamell A, et al
    SHARP INCREASE IN THE INCIDENCE AND SEVERITY OF INVASIVE STREPTOCOCCUS PYOGENES INFECTIONS IN CHILDREN AFTER THE COVID-19 PANDEMIC (2019-2023): A NATIONWIDE MULTICENTER STUDY.
    Int J Infect Dis. 2025 Jul 16:107982. doi: 10.1016/j.ijid.2025.107982.
    PubMed     Abstract available


  25. SIEBNER AS, Griesbaum J, Huus KE, Flugge J, et al
    Class switch towards IgG2 and IgG4 is more pronounced in BNT162b2 compared to mRNA-1273 COVID-19 vaccinees.
    Int J Infect Dis. 2025 Jul 16:107990. doi: 10.1016/j.ijid.2025.107990.
    PubMed     Abstract available


  26. JIA Y, Zhang L, Xie Y, Hao L, et al
    Incidence of acute respiratory infections and their associated pathogen distribution among residents in Shanghai, China: Preliminary results from community-based surveillance in the 2023-24 influenza season.
    Int J Infect Dis. 2025 Jul 3:107974. doi: 10.1016/j.ijid.2025.107974.
    PubMed     Abstract available


  27. BERG J, Linden K, Zaigham M, Domellof M, et al
    The Association between Antenatal SARS-CoV-2 Exposure and Infant Neurodevelopment at Four Months of Age: A Prospective Multicenter Cohort Survey within the COPE Study.
    Int J Infect Dis. 2025 Jul 3:107973. doi: 10.1016/j.ijid.2025.107973.
    PubMed     Abstract available


    June 2025
  28. ZHANG X, You Y, Liu J, Sun L, et al
    Effect of COVID-19 non-pharmaceutical interventions on the epidemic trends of scarlet fever in China: A population-based surveillance and modeling study.
    Int J Infect Dis. 2025 Jun 27:107969. doi: 10.1016/j.ijid.2025.107969.
    PubMed     Abstract available


  29. CHAPMAN A, Barouch DH, Lip GYH, Pliakas T, et al
    Risk of severe outcomes from COVID-19 in comorbid populations in the Omicron era: a systematic review and meta-analysis.
    Int J Infect Dis. 2025 Jun 24:107958. doi: 10.1016/j.ijid.2025.107958.
    PubMed     Abstract available


  30. PAUL E, Brown GW, Dechamps M, Kalk A, et al
    Corrigendum to "COVID-19: an 'extraterrestrial' disease?", [International Journal of Infectious Diseases, Volume 110, 155-159, September 2021].
    Int J Infect Dis. 2025;158:107951.
    PubMed    


  31. TEODORO LI, Ovsyannikova IG, Grill DE, Poland GA, et al
    Seroprevalence of RSV Antibodies in a Contemporary (2022 - 2023) Cohort of Adults.
    Int J Infect Dis. 2025 Jun 21:107964. doi: 10.1016/j.ijid.2025.107964.
    PubMed     Abstract available


  32. JOSEPH JT, Grau-Sepulveda M, Griffith BC, Lufes N, et al
    Evaluating the introduction of COVID-19 oral antivirals through a test and treat program: outcomes from a cohort study in four African countries.
    Int J Infect Dis. 2025 Jun 19:107956. doi: 10.1016/j.ijid.2025.107956.
    PubMed     Abstract available


  33. TSUCHIHASHI Y, Tamura K, Matsumoto K, Mitsushima S, et al
    Comparative analysis of streptococcal toxic shock syndrome caused by three beta-hemolytic streptococcal species in Japan.
    Int J Infect Dis. 2025 Jun 18:107962. doi: 10.1016/j.ijid.2025.107962.
    PubMed     Abstract available


  34. ESTILL J, Belayneh EG, Beale S, Keiser O, et al
    Estimation of the number of people affected by post COVID-19 condition in Switzerland in 2023: A mathematical model.
    Int J Infect Dis. 2025 Jun 18:107963. doi: 10.1016/j.ijid.2025.107963.
    PubMed     Abstract available


  35. WEE LE, Ho RWL, Lim JT, Chiew CJ, et al
    Long-term multi-systemic sequelae post-hospitalization for Omicron COVID-19 versus influenza: a retrospective cohort study.
    Int J Infect Dis. 2025 Jun 9:107946. doi: 10.1016/j.ijid.2025.107946.
    PubMed     Abstract available


    May 2025
  36. DEBIE Y, Verbruggen L, Peeters M, van Dam PA, et al
    mRNA COVID-19 vaccines induce superior IgA titers in cancer patients compared to viral vector vaccines: Implications for immunization strategies.
    Int J Infect Dis. 2025 May 23:107939. doi: 10.1016/j.ijid.2025.107939.
    PubMed     Abstract available


  37. HUANG Q, Kang L, Wei X, Gong C, et al
    Epidemiology and genetic diversity of common human coronaviruses in Beijing, 2015-2023: A prospective multicenter study.
    Int J Infect Dis. 2025 May 14:107926. doi: 10.1016/j.ijid.2025.107926.
    PubMed     Abstract available


  38. INZAULE S, Silva R, Thwin SS, Waasila J, et al
    In-hospital Mortality Among Children and Adults Hospitalized with COVID-19 in Africa Across Pre-Delta, Delta, and Omicron SARS-CoV-2 Waves.
    Int J Infect Dis. 2025 May 7:107924. doi: 10.1016/j.ijid.2025.107924.
    PubMed     Abstract available


  39. BANHOLZER N, Middelkoop K, Schmutz R, Leukes J, et al
    Infection prevention and control measures during the COVID-19 pandemic and airborne tuberculosis transmission during primary care visits in South Africa.
    Int J Infect Dis. 2025 May 6:107921. doi: 10.1016/j.ijid.2025.107921.
    PubMed     Abstract available


    April 2025
  40. BERENDS MS, Homburg M, Kupers T, Meijer EN, et al
    Impact of Pre-Existing Comorbidities and Multimorbidities, Demography and Viral Variants on Post-Acute Sequelae of COVID-19 ('Long COVID') in Dutch Primary Care: A Retrospective Cohort Study.
    Int J Infect Dis. 2025 Apr 19:107912. doi: 10.1016/j.ijid.2025.107912.
    PubMed     Abstract available


  41. CHEN W, Du M, Deng J, Liu M, et al
    Global, regional, and national trends of measles burden and its vaccination coverage among children under five years old: an updated systematic analysis from the Global Burden of Disease study 2021.
    Int J Infect Dis. 2025 Apr 15:107908. doi: 10.1016/j.ijid.2025.107908.
    PubMed     Abstract available


  42. JOLLIVET O, Urchueguia-Fornes A, Chung-Delgado K, Johannesen CK, et al
    Respiratory Syncytial Virus hospitalisation burden in children below 18 years in six European countries (2016-2023) pre- and post-COVID-19 pandemic.
    Int J Infect Dis. 2025 Apr 7:107903. doi: 10.1016/j.ijid.2025.107903.
    PubMed     Abstract available


    March 2025
  43. FANG S, Zhu L, Bai S, Tian W, et al
    Year-round infectome profiling of acute febrile respiratory illness unveiled complex epidemiological dynamics post-lifting of COVID-19 restrictions.
    Int J Infect Dis. 2025 Mar 29:107896. doi: 10.1016/j.ijid.2025.107896.
    PubMed     Abstract available


  44. LASTRUCCI V, Pacifici M, Puglia M, Alderotti G, et al
    Recent trends in hospitalizations for Respiratory Syncytial Virus after the COVID-19 pandemic and before routine immunization: seasonality and severity updates from the 2023/2024 season in Tuscany, Italy.
    Int J Infect Dis. 2025 Mar 13:107879. doi: 10.1016/j.ijid.2025.107879.
    PubMed     Abstract available


  45. MADEWELL ZJ, Wong JM, Thayer MB, Rivera-Amill V, et al
    Population-level respiratory virus-virus interactions, Puerto Rico, 2013-2023.
    Int J Infect Dis. 2025 Mar 11:107878. doi: 10.1016/j.ijid.2025.107878.
    PubMed     Abstract available


  46. LI Z, Wang Z, Wang X, Chen S, et al
    Global containment policy duration and long-term epidemic progression: a target trial emulation using COVID-19 data from 2020 to 2022.
    Int J Infect Dis. 2025 Mar 5:107871. doi: 10.1016/j.ijid.2025.107871.
    PubMed     Abstract available


  47. CAMELO S, Dioh W, Teixeira JP, Busse LW, et al
    Modulation of the Renin-Angiotensin System against COVID-19: A path forward?
    Int J Infect Dis. 2025 Mar 4:107867. doi: 10.1016/j.ijid.2025.107867.
    PubMed     Abstract available


    February 2025
  48. AKHTAR M, Hashmi AH, Manzoor S
    The Synergistic Tapestry: unraveling the interplay of Parvovirus B19 with other viruses.
    Int J Infect Dis. 2025 Feb 28:107865. doi: 10.1016/j.ijid.2025.107865.
    PubMed     Abstract available


  49. JOO H, Kim E, Huh K, Bae GH, et al
    Risk of Post-Acute Sequelae of COVID-19 and Oral Antivirals in Adults Aged Over 60 years: A Nationwide Retrospective Cohort Study.
    Int J Infect Dis. 2025 Feb 24:107850. doi: 10.1016/j.ijid.2025.107850.
    PubMed     Abstract available


  50. SHINZATO A, Hibiya K, Nishiyama N, Ikemiyagi N, et al
    Unseasonal respiratory syncytial virus epidemics during the COVID-19 pandemic: relationship between climatic factors and epidemic strain switching.
    Int J Infect Dis. 2025 Feb 8:107833. doi: 10.1016/j.ijid.2025.107833.
    PubMed     Abstract available


  51. LESLIE A, Chapman SA, Tessier KM, Tignanelli C, et al
    Beyond the Guidelines: Original Research on Real-World Outcomes of Anticoagulation and Corticosteroid in COVID-19.
    Int J Infect Dis. 2025 Feb 8:107834. doi: 10.1016/j.ijid.2025.107834.
    PubMed     Abstract available


  52. ZAMPIERI F, Michieletto F, Zanatta A
    Rise and fall of the Myth of the Good Pathogen in Evolutionary Biology and Medicine.
    Int J Infect Dis. 2025 Feb 5:107836. doi: 10.1016/j.ijid.2025.107836.
    PubMed     Abstract available


    January 2025
  53. RICCIO MD, Caini S
    Refining Influenza Epidemiology in the Post-COVID-19 Era: The Need for Complementary Approaches.
    Int J Infect Dis. 2025 Jan 18:107787. doi: 10.1016/j.ijid.2025.107787.
    PubMed    


    December 2024
  54. PETERSEN E, Hvid U, Tomori O, Pedersen AG, et al
    Possible scenarios for the spread of mpox outside the endemic focus in Africa.
    Int J Infect Dis. 2024 Dec 27:107373. doi: 10.1016/j.ijid.2024.107373.
    PubMed     Abstract available


  55. CHEN X, Chen H, Tao F, Chen Y, et al
    Global analysis of influenza epidemic characteristics in the first two seasons after lifting the non-pharmaceutical interventions for COVID-19.
    Int J Infect Dis. 2024 Dec 20:107372. doi: 10.1016/j.ijid.2024.107372.
    PubMed     Abstract available


  56. SIBOMANA O, Hakayuwa CM, Munyantore J
    Marburg Virus Reaches Rwanda: How Close Are We to a Vaccine Solution?
    Int J Infect Dis. 2024 Dec 19:107371. doi: 10.1016/j.ijid.2024.107371.
    PubMed     Abstract available


  57. WATASE M, Masaki K, Chubachi S, Namkoong H, et al
    Corrigendum to 'Impact of accumulative smoking exposure and chronic obstructive pulmonary disease on COVID-19 outcomes: report based on findings from the Japan COVID-19 task force' [IJID 128 (2023) 121-127].
    Int J Infect Dis. 2024;151:107322.
    PubMed    


  58. ANDEWEG SP, de Kassteele JV, Wang X, van Maarseveen N, et al
    Estimating the effect of COVID-19 vaccination and prior infection on Ct values as a proxy of SARS-CoV-2 viral load.
    Int J Infect Dis. 2024 Dec 9:107362. doi: 10.1016/j.ijid.2024.107362.
    PubMed     Abstract available


  59. DEQUIDT T, Richier Q, Louapre C, Ader F, et al
    Convalescent plasma in patients receiving Rituximab or Ocrelizumab for Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorder with COVID-19: A Multicenter Retrospective Study.
    Int J Infect Dis. 2024 Dec 4:107323. doi: 10.1016/j.ijid.2024.107323.
    PubMed     Abstract available


  60. IP B, Pan S, Yao A, Lau L, et al
    COVID-19 vaccination and cerebral small vessel disease progression - A prospective cohort study.
    Int J Infect Dis. 2024 Dec 3:107324. doi: 10.1016/j.ijid.2024.107324.
    PubMed     Abstract available


    November 2024
  61. PETT SL
    Predictors of hospitalisation, death and incomplete/non-recovery from SARS-CoV-2 in an ambulatory global population.
    Int J Infect Dis. 2024 Nov 26:107285. doi: 10.1016/j.ijid.2024.107285.
    PubMed     Abstract available


  62. YANG X, Zhang J, Liu Z, Chen S, et al
    Real-world effectiveness of COVID-19 vaccine in people with HIV compared with a matched HIV-negative cohort: a test-negative design.
    Int J Infect Dis. 2024 Nov 22:107310. doi: 10.1016/j.ijid.2024.107310.
    PubMed     Abstract available


  63. CHUN HM, Osawe S, Adams-Dabban S, Favaloro J, et al
    SARS-CoV-2 Serologic Surveillance Among People Living with HIV in Nigeria, April 2022-January 2023.
    Int J Infect Dis. 2024 Nov 21:107309. doi: 10.1016/j.ijid.2024.107309.
    PubMed     Abstract available


  64. VEINTIMILLA C, Miyares AA, Serrano SB, Palomino-Cabrera R, et al
    Occult COVID-19 in an immunosuppressed patient with migratory pulmonary infiltrates.
    Int J Infect Dis. 2024 Nov 19:107296. doi: 10.1016/j.ijid.2024.107296.
    PubMed     Abstract available


  65. MELLOR J, Fyles M, Paton RS, Phillips A, et al
    Assessing the Impact of SARS-CoV-2 on Influenza-Like Illness Surveillance Trends in the Community during the 2023/2024 Winter in England.
    Int J Infect Dis. 2024 Nov 16:107307. doi: 10.1016/j.ijid.2024.107307.
    PubMed     Abstract available


  66. DE BRUIJN S, Tulen AD, Rodenburg J, Boshuizen H, et al
    Post-acute sequalae of COVID-19 three to twelve months after infection: Delta versus Omicron.
    Int J Infect Dis. 2024 Nov 14:107302. doi: 10.1016/j.ijid.2024.107302.
    PubMed     Abstract available


  67. ZAR HJ, Workman L, MacGinty R, Botha M, et al
    Natural immunity and protection against variants in South African children through five COVID-19 waves: A prospective study.
    Int J Infect Dis. 2024 Nov 13:107300. doi: 10.1016/j.ijid.2024.107300.
    PubMed     Abstract available


  68. LASTRUCCI V, Pacifici M, Puglia M, Alderotti G, et al
    Erratum to 'Seasonality and severity of respiratory syncytial virus during the COVID-19 pandemic: a dynamic cohort study'.
    Int J Infect Dis. 2024;149:107286.
    PubMed    


  69. GRIFFITHS M, Hatabah D, Sullivan P, Mantus G, et al
    Corrigendum to "Incidence of SARS-CoV-2 seropositivity in pediatric healthcare workers prior to widespread vaccination: A 5-month longitudinal cohort study" [Internation Journal of Infectious Diseases, volume 144 (2024) 107064].
    Int J Infect Dis. 2024;149:107278.
    PubMed    


  70. NAVEED Z, Li J, Wilton J, Naus M, et al
    Healthcare utilization among COVID-19 mRNA vaccine-associated myocarditis cases: a matched retrospective cohort study.
    Int J Infect Dis. 2024 Nov 1:107287. doi: 10.1016/j.ijid.2024.107287.
    PubMed     Abstract available


  71. EPSTEIN-SHUMAN A, Hunt JH, Caturegli P, Winguth P, et al
    Autoantibodies Directed Against Interferon Alpha, Nuclear Antigens, Cardiolipin, and Beta 2 Glycoprotein 1 Are Not Induced By SARS-CoV-2 or Associated with Long COVID.
    Int J Infect Dis. 2024 Nov 1:107289. doi: 10.1016/j.ijid.2024.107289.
    PubMed     Abstract available


    October 2024
  72. AZHAR EI, Velavan TP, Rungsung I, Traore T, et al
    Corrigendum to "Middle East respiratory syndrome coronavirus-a 10-year (2012-2022) global analysis of human and camel infections, genomic sequences, lineages, and geographical origins" [International Journal of Infectious Diseases (2023), volume 131,
    Int J Infect Dis. 2024;149:107261.
    PubMed    


  73. TANG YS, Tan CW, Chong KC, Chen C, et al
    Determination of T cell response against XBB variants in adults who received either monovalent wild type inactivated whole virus or mRNA vaccine or bivalent WT/BA.4-5 COVID-19 mRNA vaccine as the additional booster.
    Int J Infect Dis. 2024 Oct 17:107271. doi: 10.1016/j.ijid.2024.107271.
    PubMed     Abstract available


  74. DE LAZZARI E, Nomah DK, Blanco JL, Rico N, et al
    Prevalence, risk factors and the impact of tenofovir treatment in SARS-CoV-2 infection and COVID-19 disease among people living with HIV. A cross-sectional population-based study.
    Int J Infect Dis. 2024 Oct 16:107266. doi: 10.1016/j.ijid.2024.107266.
    PubMed     Abstract available


  75. ELLINGJORD-DALE M, Nygaard AB, Stoer NC, Bo R, et al
    Temporal trajectories of long-COVID symptoms in adults with 22 months follow-up in a prospective cohort study in Norway.
    Int J Infect Dis. 2024 Oct 15:107263. doi: 10.1016/j.ijid.2024.107263.
    PubMed     Abstract available


  76. COLANERI M, Fama F, Fassio F, Holmes D, et al
    Impact of Early Antiviral Therapy on SARS-CoV-2 Clearance Time in High-Risk COVID-19 subjects: A Propensity Score Matching Study.
    Int J Infect Dis. 2024 Oct 9:107265. doi: 10.1016/j.ijid.2024.107265.
    PubMed     Abstract available


  77. CELLA E, Fonseca V, Branda F, Tosta S, et al
    Integrated analyses of the transmission history of SARS-CoV-2 and its association with molecular evolution of the virus underlining the pandemic outbreaks in Italy, 2019-2023.
    Int J Infect Dis. 2024 Oct 8:107262. doi: 10.1016/j.ijid.2024.107262.
    PubMed     Abstract available


    September 2024
  78. NAGASAWA K, Ohata M, Igarashi A, Arashiro T, et al
    Prospective hospital-based cohort studies of Respiratory Syncytial Virus (RSV) infections in infants under one year during and after the SARS-CoV-2 pandemic in Japan.
    Int J Infect Dis. 2024 Sep 27:107252. doi: 10.1016/j.ijid.2024.107252.
    PubMed     Abstract available


  79. TAKAHASHI H, Morikawa M, Satake Y, Nagamatsu H, et al
    Diagnostic Utility of Pharyngeal Follicular Structures in COVID-19: A Large-scale Cross-Sectional Study.
    Int J Infect Dis. 2024 Sep 21:107244. doi: 10.1016/j.ijid.2024.107244.
    PubMed     Abstract available


  80. LEE JA, Jang H, Ahn SM, Seong JE, et al
    Estimates of Vaccine Effectiveness of the Updated Monovalent XBB.1.5 COVID-19 Vaccine Against Symptomatic SARS-CoV-2 Infection, Hospitalization, and Receipt of Oxygen Therapy in South Korea - October 26 to December 31, 2023.
    Int J Infect Dis. 2024 Sep 20:107249. doi: 10.1016/j.ijid.2024.107249.
    PubMed     Abstract available


  81. CERQUEIRA-SILVA T, Boaventura VS, Pearce N, Barral-Netto M, et al
    Indirect effectiveness of COVID-19 vaccines in the pre-omicron and omicron periods: a nation-wide test-negative case-control study in Brazil.
    Int J Infect Dis. 2024 Sep 18:107241. doi: 10.1016/j.ijid.2024.107241.
    PubMed     Abstract available


  82. KAWAGUCHI A, Nagaoka K, Kawasuji H, Kawagishi T, et al
    COVID-19 complicated with severe M1(UK)-lineage Streptococcus pyogenes infection in elderly patients: A report of two cases.
    Int J Infect Dis. 2024 Sep 18:107246. doi: 10.1016/j.ijid.2024.107246.
    PubMed     Abstract available


  83. MARGALIT I, Weiss-Ottolenghi Y, Panet E, Indenbaum V, et al
    SARS-CoV-2 Omicron XBB.1 variant outbreak in a defined cohort: an epidemiological investigation incorporating longitudinal assessment of humoral response.
    Int J Infect Dis. 2024 Sep 11:107240. doi: 10.1016/j.ijid.2024.107240.
    PubMed     Abstract available


  84. SOW SO, Tapia MD, Haidara FC, Diallo F, et al
    Safety, reactogenicity, and immunogenicity of ZR-202-CoV and ZR-202a-CoV recombinant vaccines compared with Comirnaty(R): a randomized, observer-blind, controlled, phase 1 study.
    Int J Infect Dis. 2024 Sep 11:107237. doi: 10.1016/j.ijid.2024.107237.
    PubMed     Abstract available


  85. DUARTE-HERRERA ID, Lopez-Martinez C, Rodriguez-Garcia R, Parra D, et al
    Identification of host endotypes using peripheral blood transcriptomics in a prospective cohort of patients with endocarditis.
    Int J Infect Dis. 2024 Sep 6:107235. doi: 10.1016/j.ijid.2024.107235.
    PubMed     Abstract available


  86. HUBACEK JA, Capkova N, Bobak M, Pikhart H, et al
    Association between FTO polymorphism and COVID-19 mortality among older adults: a population-based cohort study.
    Int J Infect Dis. 2024 Sep 5:107232. doi: 10.1016/j.ijid.2024.107232.
    PubMed     Abstract available


  87. BEEGLE K, Demombynes G, de Walque D, Gubbins P, et al
    COVID-19 Increased Existing Gender Mortality Gaps in High Income More than Middle Income Countries.
    Int J Infect Dis. 2024 Sep 2:107167. doi: 10.1016/j.ijid.2024.107167.
    PubMed     Abstract available


    August 2024
  88. LASTRUCCI V, Pacifici M, Puglia M, Alderotti G, et al
    Seasonality and severity of respiratory syncytial virus during the COVID-19 pandemic: a dynamic cohort study.
    Int J Infect Dis. 2024 Aug 31:107231. doi: 10.1016/j.ijid.2024.107231.
    PubMed     Abstract available


  89. OKADA Y, Ueda M, Nishiura H
    Reconstructing the age-structured case count of COVID-19 from sentinel surveillance data in Japan: a modeling study.
    Int J Infect Dis. 2024 Aug 27:107223. doi: 10.1016/j.ijid.2024.107223.
    PubMed     Abstract available


  90. LOMBARDI A, Colaneri M, Azzara C, Saltini P, et al
    Solid organ transplant in recipients with ongoing SARS-CoV-2 infection: A systematic review of case reports and series.
    Int J Infect Dis. 2024 Aug 21:107214. doi: 10.1016/j.ijid.2024.107214.
    PubMed     Abstract available


  91. GALASSI FM, Cofone L, Pindinello I, Ribatti D, et al
    The Curfew Bell and the COVID-19 Pandemic: A Historical-Medical Perspective based on the Italian Case.
    Int J Infect Dis. 2024 Aug 21:107217. doi: 10.1016/j.ijid.2024.107217.
    PubMed     Abstract available


  92. KHAN S, Yetiskul E, Khan DF, Khan MWZ, et al
    Hantavirus-Induced Cardiac Tamponade: A Diagnostic Dilemma.
    Int J Infect Dis. 2024 Aug 16:107212. doi: 10.1016/j.ijid.2024.107212.
    PubMed     Abstract available


  93. CHOI WJ, Lee J, Choi K, Kim DM, et al
    Outcomes of hematopoietic stem cell transplantation in patients with SARS-CoV-2 infection during the Omicron era.
    Int J Infect Dis. 2024 Aug 13:107207. doi: 10.1016/j.ijid.2024.107207.
    PubMed     Abstract available


  94. SONG XD, Yang GJ, Shi C, Jiang XL, et al
    Finite immune imprinting on neutralizing antibody responses to Omicron subvariants by repeated vaccinations.
    Int J Infect Dis. 2024 Aug 6:107198. doi: 10.1016/j.ijid.2024.107198.
    PubMed     Abstract available


  95. KIMURA M, Fujiwara S, Kuroda H, Kanamori M, et al
    Choroid plexitis caused by Burkholderia cepacia complex following coronavirus disease 2019.
    Int J Infect Dis. 2024 Aug 3:107201. doi: 10.1016/j.ijid.2024.107201.
    PubMed     Abstract available


  96. ALBERTO RC, Patricia AM, Hugo B, Delia O, et al
    Real-world effectiveness of the CoronaVac vaccine in a retrospective population-based cohort in four Colombian Cities 2021-2022.
    Int J Infect Dis. 2024 Aug 2:107156. doi: 10.1016/j.ijid.2024.107156.
    PubMed     Abstract available


    July 2024
  97. JANGIAM W, Swangpun K, Iamsirithaworn S, Piriyasatit S, et al
    Relative vaccine effectiveness of ChAdOx1/AZD1222 vaccines as booster dose via intradermal injection with a one-fifth dose compared with the intramuscular injection in the prevention of SAR-CoV-2 infections in Phuket - A Retrospective Cohort Study.
    Int J Infect Dis. 2024 Jul 31:107179. doi: 10.1016/j.ijid.2024.107179.
    PubMed     Abstract available


  98. SHU Y, He L, Liu C
    Impact of Anti-fibrotic Medications on Post-COVID-19 Pulmonary Fibrosis: A Systematic Review and Meta-analysis.
    Int J Infect Dis. 2024 Jul 31:107193. doi: 10.1016/j.ijid.2024.107193.
    PubMed     Abstract available


  99. THANH TT, Tu NTK, Nguyet LA, Thuy CT, et al
    Immunogenicity of Abdala COVID-19 vaccine in Vietnamese people after primary and booster vaccinations: a prospective observational study in Vietnam.
    Int J Infect Dis. 2024 Jul 31:107173. doi: 10.1016/j.ijid.2024.107173.
    PubMed     Abstract available


  100. SUN Y, Dai L, Shan Y, Yang Y, et al
    Pathogen characteristics of respiratory infections in the season after the COVID-19 pandemic between August and December 2023: evidence from direct-to-consumer testing-based surveillance in Guangzhou and Beijing, China.
    Int J Infect Dis. 2024 Jul 27:107195. doi: 10.1016/j.ijid.2024.107195.
    PubMed     Abstract available


  101. PEREZ-GUZMAN PN, Chanda SL, Schaap A, Shanaube K, et al
    Pandemic burden in low-income settings and impact of limited and delayed interventions: a granular modelling analysis of COVID-19 in Kabwe, Zambia.
    Int J Infect Dis. 2024 Jul 25:107182. doi: 10.1016/j.ijid.2024.107182.
    PubMed     Abstract available


  102. MI X, Zhang X, Dai Z, Yan X, et al
    Clinical characteristics and outcomes of lung transplantation in patients with severe COVID-19 infection: A systematic review and meta-analysis.
    Int J Infect Dis. 2024 Jul 16:107176. doi: 10.1016/j.ijid.2024.107176.
    PubMed     Abstract available


  103. SHOJI R, Fukuda K, Mizobuchi T, Arakawa Y, et al
    Reactivation of herpes simplex virus 2 presenting as recurrent acute retinal necrosis following COVID-19 vaccination.
    Int J Infect Dis. 2024 Jul 16:107170. doi: 10.1016/j.ijid.2024.107170.
    PubMed     Abstract available


  104. STEMLER J, Yeghiazaryan L, Stephan C, Mohn KG, et al
    Immunogenicity, reactogenicity and safety of a second booster with BNT162b2 or full-dose mRNA-1273: a randomised VACCELERATE trial in adults >/=75 years (EU-COVAT-1-AGED Part B).
    Int J Infect Dis. 2024 Jul 9:107161. doi: 10.1016/j.ijid.2024.107161.
    PubMed     Abstract available


  105. LIN DY, Wang J, Anstrom KJ, LaVange LM, et al
    Efficacy of Infliximab, Abatacept, and Cenicriviroc for the Treatment of Adults Hospitalized with COVID-19 Pneumonia.
    Int J Infect Dis. 2024 Jul 6:107168. doi: 10.1016/j.ijid.2024.107168.
    PubMed     Abstract available


  106. GUNTHER J, Ziert Y, Andresen K, Pecks U, et al
    Variability in COVID-19 Symptom Presentation During Pregnancy and its Impact on Maternal and Infant Outcomes Across the Pandemic.
    Int J Infect Dis. 2024 Jul 4:107157. doi: 10.1016/j.ijid.2024.107157.
    PubMed     Abstract available


  107. ZHENG Y, Jia S, Tang L, Yu L, et al
    Recent symptomatic omicron infection reduced COVID-19 pneumonia risk during reinfection: A computed tomography-based cohort study.
    Int J Infect Dis. 2024 Jul 4:107164. doi: 10.1016/j.ijid.2024.107164.
    PubMed     Abstract available


  108. MARTIN-ESCOLANO J, Salto-Alejandre S, Infante-Dominguez C, Carretero-Ledesma M, et al
    COVID-19 in patients with haematologic malignancies: effect of RNAemia on clinical outcome in vaccinated patients.
    Int J Infect Dis. 2024 Jul 3:107163. doi: 10.1016/j.ijid.2024.107163.
    PubMed     Abstract available


  109. KHALIL A, Samara A, Campbell H, Ladhani SN, et al
    Recent increase in infant pertussis cases in Europe and the critical importance of antenatal immunisations: we must do better...now.
    Int J Infect Dis. 2024 Jul 1:107148. doi: 10.1016/j.ijid.2024.107148.
    PubMed     Abstract available


    June 2024
  110. GOH YS, Fong SW, Hor PX, Loh CY, et al
    Imprinting of IgA responses in previously infected individuals receiving bivalent mRNA vaccines (WT and BA.4/BA.5 or WT and BA.1).
    Int J Infect Dis. 2024 Jun 28:107147. doi: 10.1016/j.ijid.2024.107147.
    PubMed     Abstract available


  111. TAKASHITA E, Ichikawa M, Fujisaki S, Morita H, et al
    Antiviral susceptibility of SARS-CoV-2 and influenza viruses from 3 co-infected pediatric patients.
    Int J Infect Dis. 2024 Jun 27:107134. doi: 10.1016/j.ijid.2024.107134.
    PubMed     Abstract available


  112. DASHTBAN A, Mizani M, Pasea L, Tomlinson C, et al
    Vaccinations, cardiovascular drugs, hospitalisation and mortality in COVID-19 and Long COVID.
    Int J Infect Dis. 2024 Jun 26:107155. doi: 10.1016/j.ijid.2024.107155.
    PubMed     Abstract available


  113. CHOI YJ, Kim HN, Lee J, Nham E, et al
    Erythema nodosum as an unusual skin manifestation of long COVID: A case report.
    Int J Infect Dis. 2024 Jun 25:107152. doi: 10.1016/j.ijid.2024.107152.
    PubMed     Abstract available


  114. HASEGAWA J, Sekizawa A, Tanaka H, Katsuragi S, et al
    Infection route associated with invasive group A streptococcal toxic shock syndrome in maternal deaths: Nationwide analysis of maternal mortalities in Japan.
    Int J Infect Dis. 2024 Jun 25:107154. doi: 10.1016/j.ijid.2024.107154.
    PubMed     Abstract available


  115. WAN EYF, Wang B, Lee AL, Zhou J, et al
    Comparative Effectiveness and Safety of BNT162b2 and CoronaVac in Hong Kong: A Target Trial Emulation.
    Int J Infect Dis. 2024 Jun 21:107149. doi: 10.1016/j.ijid.2024.107149.
    PubMed     Abstract available


  116. JEDLICKA P
    Furst et al. fail to address crucial biases other than the Healthy vaccinee effect.
    Int J Infect Dis. 2024 Jun 20:107143. doi: 10.1016/j.ijid.2024.107143.
    PubMed    


  117. SMID M, Tucek V, Madar R, Tachezy R, et al
    No evidence of a "healthy vaccinee effect" in COVID-19 vaccination data from the Czech Republic.
    Int J Infect Dis. 2024 Jun 19:107144. doi: 10.1016/j.ijid.2024.107144.
    PubMed    


  118. HUIBERTS AJ, van den Hof S, Knol MJ
    Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection: repeat analyses with updated data for the prospective cohort study in the Netherlands from July 2021 to June 2022.
    Int J Infect Dis. 2024 Jun 18:107127. doi: 10.1016/j.ijid.2024.107127.
    PubMed    


  119. FARMER G, Sikdar KC, Lo T, Conly J, et al
    Real-world evidence of sotrovimab effectiveness for preventing severe outcomes in patients with COVID-19: A quality improvement propensity matched retrospective cohort study of a pan-provincial program in Alberta, Canada.
    Int J Infect Dis. 2024 Jun 14:107136. doi: 10.1016/j.ijid.2024.107136.
    PubMed     Abstract available


    May 2024
  120. LOUBET P, Lelievre JD, Francois A, Botelho-Nevers E, et al
    Humoral response after mRNA COVID-19 primary vaccination and single booster dose in people living with HIV compared to controls: a French nationwide multicenter cohort study - ANRS0001s COV-POPART.
    Int J Infect Dis. 2024 May 31:107110. doi: 10.1016/j.ijid.2024.107110.
    PubMed     Abstract available


  121. DE MENDOZA C, Lozano AB, Rando A, Carmen Nieto MD, et al
    The incidence of HIV-2 infection in Spain is declining - a registry data analysis.
    Int J Infect Dis. 2024 May 30:107076. doi: 10.1016/j.ijid.2024.107076.
    PubMed     Abstract available


  122. MAHYUDDIN AP, Swa HLF, Weng R, Zhang J, et al
    COVID-19 vaccination before or during pregnancy results in high, sustained maternal neutralizing activity to SARS-CoV2 wild-type and Delta/Omicron variants of concern, particularly following a booster dose or infection.
    Int J Infect Dis. 2024 May 30:107121. doi: 10.1016/j.ijid.2024.107121.
    PubMed     Abstract available


  123. REEKIE J, Stovring H, Nielsen H, Johansen IS, et al
    Development of antibody levels and subsequent decline in individuals with vaccine induced and hybrid immunity to SARS-CoV-2.
    Int J Infect Dis. 2024 May 25:107111. doi: 10.1016/j.ijid.2024.107111.
    PubMed     Abstract available


  124. LI Y, Wu Z, Yan Y, Shi Y, et al
    Corrigendum to "Prevalence of respiratory viruses among hospitalized children with lower respiratory tract infections during the COVID-19 pandemic in Wuhan, China" [International Journal of Infectious Diseases 139 (2024) pages 6-12].
    Int J Infect Dis. 2024;145:107056.
    PubMed    


  125. RAMONFAUR D, Ayad N, Liu PHZ, Zhou J, et al
    The global clinical studies of long COVID.
    Int J Infect Dis. 2024 May 21:107105. doi: 10.1016/j.ijid.2024.107105.
    PubMed     Abstract available


  126. CHEMAITELLY H, Akhtar N, Jerdi SA, Kamran S, et al
    Association between COVID-19 vaccination and stroke: a nationwide case-control study in Qatar.
    Int J Infect Dis. 2024 May 20:107095. doi: 10.1016/j.ijid.2024.107095.
    PubMed     Abstract available


  127. ZHANG D, Liu S, Peng B, Shi X, et al
    Effects of the timing of maternal SARS-CoV-2 infection and vaccination status on placental transfer of antibodies to neonates: a cross-sectional study.
    Int J Infect Dis. 2024 May 16:107098. doi: 10.1016/j.ijid.2024.107098.
    PubMed     Abstract available


  128. BOJJA D, Zuo S, Townsend JP
    Sufficient COVID-19 quarantine and testing on international travelers to forestall cross-border transmission after China's removal of the Zero-COVID policy in early 2023.
    Int J Infect Dis. 2024 May 13:107097. doi: 10.1016/j.ijid.2024.107097.
    PubMed     Abstract available


  129. VAZQUEZ E, de Gregorio-Vicente O, Soriano V, Alvarez-Dominguez C, et al
    Increased incidence and mortality from Listeria monocytogenes infection in Spain.
    Int J Infect Dis. 2024 May 9:107089. doi: 10.1016/j.ijid.2024.107089.
    PubMed     Abstract available


  130. KYI D, Xiao Y, Wang X, Feng S, et al
    Predominance of A2063G mutant strains in the Mycoplasma pneumoniae epidemic in children-a clinical and epidemiological study in 2023 in Wuhan, China.
    Int J Infect Dis. 2024 May 9:107074. doi: 10.1016/j.ijid.2024.107074.
    PubMed     Abstract available


  131. VAN VOORDEN J, de Groot CJM, Ris-Stalpers C, Afink GB, et al
    Corrigendum to "COVID-19 mRNA vaccination during pregnancy does not harm syncytiotrophoblast development" [International Journal of Infectious Diseases, 140C (2024) pages 95-98].
    Int J Infect Dis. 2024;144:107068.
    PubMed    


  132. LIN DY, Xu Y, Gu Y, Sunny SK, et al
    Impact of Booster Vaccination Interval on SARS-CoV-2 Infection, Hospitalization, and Death.
    Int J Infect Dis. 2024 May 3:107084. doi: 10.1016/j.ijid.2024.107084.
    PubMed     Abstract available


  133. SCOTT AJ, Limbada M, Perumal T, Jaumdally S, et al
    Integrating molecular and radiological screening tools during community-based active case-finding for tuberculosis and COVID-19 in southern Africa.
    Int J Infect Dis. 2024 May 1:107081. doi: 10.1016/j.ijid.2024.107081.
    PubMed     Abstract available


  134. XIANG Y, Feng Y, Qiu J, Zhang R, et al
    Association of COVID-19 vaccination with risks of hospitalization due to cardiovascular and other diseases: a study using data from the UK Biobank.
    Int J Infect Dis. 2024 May 1:107080. doi: 10.1016/j.ijid.2024.107080.
    PubMed     Abstract available


    April 2024
  135. MURRAY HC, Muleme M, Cooper D, McNamara BJ, et al
    Prevalence, risk factors and outcomes of secondary infections among hospitalised patients with COVID-19 or post-COVID-19 conditions in Victoria, 2020-2023.
    Int J Infect Dis. 2024 Apr 30:107078. doi: 10.1016/j.ijid.2024.107078.
    PubMed     Abstract available


  136. YAN X, Zhao X, Du Y, Wang H, et al
    Dynamics of anti-SARS-CoV-2 IgG antibody responses following breakthrough infection and the predicted protective efficacy: a longitudinal community-based population study in China.
    Int J Infect Dis. 2024 Apr 30:107075. doi: 10.1016/j.ijid.2024.107075.
    PubMed     Abstract available


  137. MARTINEZ-FIERRO ML, Perez-Favila A, Alfaro SMZ, Oropeza-de Lara SA, et al
    Gene variants rs5182, rs2074192, and rs4343 in the Renin-Angiotensin-Aldosterone system are associated with symptom severity, higher odds of hospitalization, and death in COVID-19.
    Int J Infect Dis. 2024 Apr 30:107067. doi: 10.1016/j.ijid.2024.107067.
    PubMed     Abstract available


  138. XIE H, Zhang J, Bai S, Lv M, et al
    The contributions of vaccination and natural infection to the production of neutralizing antibodies against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) prototype strain and variants.
    Int J Infect Dis. 2024 Apr 24:107060. doi: 10.1016/j.ijid.2024.107060.
    PubMed     Abstract available


  139. VERGORI A, Cozzi-Lepri A, Tavelli A, Mazzotta V, et al
    SARS-CoV-2 mRNA vaccination and short-term changes in viral load and CD4/CD8 T cell counts in people living with HIV.
    Int J Infect Dis. 2024 Apr 19:107065. doi: 10.1016/j.ijid.2024.107065.
    PubMed     Abstract available


  140. GRIFFITHS M, Hatabah D, Sullivan P, Mantus G, et al
    Incidence of SARS-CoV-2 Seropositivity in Pediatric Healthcare Workers Prior to Widespread Vaccination: A Five-month Longitudinal Cohort Study.
    Int J Infect Dis. 2024 Apr 17:107064. doi: 10.1016/j.ijid.2024.107064.
    PubMed     Abstract available


  141. RICCIO MD, Caini S, Bonaccorsi G, Lorini C, et al
    Global analysis of respiratory viral circulation and timing of epidemics in the pre-COVID-19 and COVID-19 pandemic eras, based on data from the Global Influenza Surveillance and Response System (GISRS).
    Int J Infect Dis. 2024 Apr 16:107052. doi: 10.1016/j.ijid.2024.107052.
    PubMed     Abstract available


  142. GLASER N, Diexer S, Klee B, Purschke DO, et al
    The contribution of SARS-CoV-2 to the burden of acute respiratory infections in winter season 2022/2023: Results from the DigiHero study.
    Int J Infect Dis. 2024 Apr 15:107057. doi: 10.1016/j.ijid.2024.107057.
    PubMed     Abstract available


  143. GRONING R, Walde J, Ahlm C, Forsell MN, et al
    Intravenous immunoglobulin therapy for COVID-19 in immunocompromised patients: a retrospective cohort study.
    Int J Infect Dis. 2024 Apr 12:107046. doi: 10.1016/j.ijid.2024.107046.
    PubMed     Abstract available


  144. LIEW YX, Ho AYL, Wong GC, Chung SJ, et al
    A retrospective study of intravenous pentamidine for PCP prophylaxis in adult patients with hematological malignancies - its utility during respiratory virus pandemics.
    Int J Infect Dis. 2024 Apr 12:107059. doi: 10.1016/j.ijid.2024.107059.
    PubMed     Abstract available


  145. CHEN H, Yu L, Wang L, Zhang J, et al
    Demographic characteristics and risk factors for invasive fungal sinusitis in the context of COVID-19: A systematic review and meta-analysis.
    Int J Infect Dis. 2024 Apr 11:107054. doi: 10.1016/j.ijid.2024.107054.
    PubMed     Abstract available


  146. VERGORI A, Lepri AC, Chiuchiarelli M, Mazzotta V, et al
    Risk of SARS-CoV-2 infection in patients with hematologic diseases receiving tixagevimab/cilgavimab as pre-exposure prophylaxis in most recent Omicron sublineages era.
    Int J Infect Dis. 2024 Apr 11:107042. doi: 10.1016/j.ijid.2024.107042.
    PubMed     Abstract available


  147. SLURINK IAL, van den Houdt SCM, Mertens G
    Who develops long COVID? Longitudinal pre-pandemic predictors of long COVID and symptom clusters in a representative Dutch population.
    Int J Infect Dis. 2024 Apr 10:107048. doi: 10.1016/j.ijid.2024.107048.
    PubMed     Abstract available


  148. YU J, Zhang K, Chen T, Lin R, et al
    Temporal patterns of organ dysfunction in COVID-19 patients hospitalized in the intensive care unit: A group-based multitrajectory modelling analysis.
    Int J Infect Dis. 2024 Apr 9:107045. doi: 10.1016/j.ijid.2024.107045.
    PubMed     Abstract available


  149. FAVRESSE J, Gillot C, Cabo J, David C, et al
    Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1 and JN.1 six months after the BNT162b2 bivalent booster.
    Int J Infect Dis. 2024 Apr 5:107028. doi: 10.1016/j.ijid.2024.107028.
    PubMed     Abstract available


  150. TAMURA K, Shimbashi R, Kasamatsu A, Chang B, et al
    Unveiling the role of preceding seasonal influenza in the development of bacteremic pneumococcal pneumonia in older adults before the COVID-19 pandemic in Japan.
    Int J Infect Dis. 2024 Apr 5:107024. doi: 10.1016/j.ijid.2024.107024.
    PubMed     Abstract available


  151. MARKUSSEN DL, Kommedal O, Knoop ST, Ebbesen MH, et al
    Microbial aetiology of community-acquired pneumonia in hospitalized adults: a prospective study utilising comprehensive molecular testing.
    Int J Infect Dis. 2024 Apr 4:107019. doi: 10.1016/j.ijid.2024.107019.
    PubMed     Abstract available


  152. CORRECHER-MARTINEZ E, Lopez-Lacort M, Munoz-Quiles C, Diez-Domingo J, et al
    Risk of herpes zoster in adults with SARS-CoV-2 infection in Spain: a population-based, retrospective cohort study.
    Int J Infect Dis. 2024 Apr 2:107037. doi: 10.1016/j.ijid.2024.107037.
    PubMed     Abstract available


    March 2024
  153. SALVADORI N, Jourdain G, Krittayaphong R, Siripongboonsitti T, et al
    Molnupiravir versus favipiravir in at-risk outpatients with COVID-19: a randomized controlled trial in Thailand.
    Int J Infect Dis. 2024 Mar 30:107021. doi: 10.1016/j.ijid.2024.107021.
    PubMed     Abstract available


  154. WEIRAUCH T, Burger G, Cadar D, Gabriel M, et al
    Vaccine-derived Yellow Fever in an immunocompromised patient on anti-CD20-antibody therapy and its treatment with Sofosbuvir.
    Int J Infect Dis. 2024 Mar 21:107017. doi: 10.1016/j.ijid.2024.107017.
    PubMed     Abstract available


  155. CHEUNG YYH, Lau EHY, Yin G, Lin Y, et al
    Joint analysis of vaccination effectiveness and antiviral drug effectiveness for COVID-19: a causal inference approach.
    Int J Infect Dis. 2024 Mar 21:107012. doi: 10.1016/j.ijid.2024.107012.
    PubMed     Abstract available


  156. MINK S, Drexel H, Leiherer A, Frick M, et al
    Interplay of inflammatory markers and anti-SARS-CoV-2 antibodies in COVID-19 mortality: a prospective cohort study.
    Int J Infect Dis. 2024 Mar 21:107016. doi: 10.1016/j.ijid.2024.107016.
    PubMed     Abstract available


  157. HOSOZAWA M, Hori M, Hayama-Terada M, Arisa I, et al
    Prevalence and risk factors of post-coronavirus disease 2019 condition among children and adolescents in Japan: A matched case-control study in the general population.
    Int J Infect Dis. 2024 Mar 12:107008. doi: 10.1016/j.ijid.2024.107008.
    PubMed     Abstract available


  158. AGUILAR TICONA JP, Xiao M, Li D, Nery JN, et al
    Corrigendum to "Extensive transmission of SARS-CoV-2 BQ.1* variant in a population with high levels of hybrid immunity: A prevalence survey" [International Journal of Infectious Diseases 139 (2024) 159-167].
    Int J Infect Dis. 2024;141:106964.
    PubMed    


  159. REES C, Swift B, Haldar P
    State of art of the detection of M. tuberculosis during TB infection by blood tests using the phage technology.
    Int J Infect Dis. 2024 Mar 4:106991. doi: 10.1016/j.ijid.2024.106991.
    PubMed     Abstract available


    February 2024
  160. BOUWMANS P, Malahe SRK, Messchendorp AL, Vart P, et al
    Post COVID-19 condition imposes significant burden in patients with advanced chronic kidney disease: a nested case-control study.
    Int J Infect Dis. 2024 Feb 28:106990. doi: 10.1016/j.ijid.2024.106990.
    PubMed     Abstract available


  161. PETRAS M, Janovska D, Lomozova D, Franklova M, et al
    Understanding the time-driven shifts of vaccine effectiveness against any and severe COVID-19 before and after the surge of Omicron variants within 2.5 years of vaccination: a meta-regression.
    Int J Infect Dis. 2024 Feb 26:106986. doi: 10.1016/j.ijid.2024.106986.
    PubMed     Abstract available


  162. SYLVAIN L, Donatien K, Kadidia K, Viviane C, et al
    SARS-CoV-2 seroprevalence in vaccine-naive participants from the Democratic Republic of Congo, Guinea, Liberia, and Mali.
    Int J Infect Dis. 2024 Feb 26:106985. doi: 10.1016/j.ijid.2024.106985.
    PubMed     Abstract available


  163. DADU A, Yedilbayev A, Migliori GB, Ahmedov S, et al
    PASS to End TB in Europe: Accelerated efforts on Prevention and Systematic Screening to End Tuberculosis in the WHO European Region by 2030.
    Int J Infect Dis. 2024 Feb 23:S1201-9712(24)00051.
    PubMed     Abstract available


  164. FURST T, Bazalova A, Frycak T, Janosek J, et al
    Does the healthy vaccinee bias rule them all? Association of COVID-19 vaccination status and all cause mortality from an analysis of data from 2.2 million individual health records.
    Int J Infect Dis. 2024 Feb 22:S1201-9712(24)00046.
    PubMed     Abstract available


  165. HUANG L, Tong X, Cui J, Du X, et al
    Recurrent and persistent fever after SARS-CoV-2 infection in patients with follicular lymphoma: A case series.
    Int J Infect Dis. 2024;141:106973.
    PubMed     Abstract available


  166. IKEBE T, Okuno R, Uchitani Y, Yamaguchi T, et al
    Epidemiological shifts in and impact of COVID-19 on streptococcal toxic shock syndrome in Japan: A genotypic analysis of Group A Streptococcus isolates.
    Int J Infect Dis. 2024 Feb 19:S1201-9712(24)00022.
    PubMed     Abstract available


  167. BERENTSCHOT JC, Martine Bek L, Heijenbrok-Kal MH, van den Berg-Emons RJG, et al
    Acute COVID-19 treatment is not associated with health problems 2 years after hospitalization.
    Int J Infect Dis. 2024 Feb 15:S1201-9712(24)00036.
    PubMed     Abstract available


  168. BIANCHI FP, Rizzi D, Daleno A, Stefanizzi P, et al
    Assessing the temporal and cause-effect relationship between myocarditis and mRNA COVID-19 vaccines. A retrospective observational study.
    Int J Infect Dis. 2024 Feb 14:S1201-9712(24)00028.
    PubMed     Abstract available


  169. TANG Q, Xie X, Peng L, Yang L, et al
    Pre-existing Renal Graft Dysfunction As A Major Risk Factor for SARS-CoV-2 Omicron Variant Pneumonia: a Post-Infection Cross-Sectional Study of 312 Immunosuppressed Renal Transplant Recipients.
    Int J Infect Dis. 2024 Feb 13:S1201-9712(24)00030.
    PubMed     Abstract available


  170. DOHERTY TM, Pasquale AD, Finnegan G, Lele J, et al
    Sustaining the momentum for adult vaccination post-COVID-19 to leverage the global uptake of life-course immunisation: a scoping review.
    Int J Infect Dis. 2024 Feb 12:S1201-9712(24)00031.
    PubMed     Abstract available


  171. FUENTE A, Postigo T, Ferri FS, Dominguez-Gil M, et al
    Synergistic impact of N-antigenemia profiled by a rapid antigen test and low anti-S1 antibodies on the risk of hospitalization in COVID-19.
    Int J Infect Dis. 2024 Feb 2:S1201-9712(24)00019.
    PubMed     Abstract available


  172. XIA Q, Yang Y, Wang F, Huang Z, et al
    Case fatality rates of COVID-19 during epidemic periods of variants of concern: a meta-analysis by continents.
    Int J Infect Dis. 2024 Feb 1:S1201-9712(24)00018.
    PubMed     Abstract available


    January 2024
  173. VOORDEN AJV, Groot CJM, Ris-Stalpers C, Afink GB, et al
    COVID-19 mRNA vaccination during pregnancy does not harm syncytiotrophoblast development.
    Int J Infect Dis. 2024 Jan 25:S1201-9712(24)00015.
    PubMed     Abstract available


    December 2023
  174. PUGNI L, Crippa BL, Raimondi F, Vento G, et al
    SARS-CoV-2 perinatal transmission and neonatal outcomes across four different waves of COVID-19 pandemic: a nationwide prospective cohort study from the Italian Society of Neonatology.
    Int J Infect Dis. 2023 Dec 27:S1201-9712(23)00814.
    PubMed     Abstract available


  175. BOWN A, Sweed A, Catton M, Cowne JN, et al
    Detection of SARS-CoV-2 BA.2.86 by lateral flow devices.
    Int J Infect Dis. 2023 Dec 25:S1201-9712(23)00813.
    PubMed     Abstract available


  176. SALMON D, Slama D, Linard F, Dumesges N, et al
    Long COVID patients continue to experience significant symptoms at 12 months and factors associated with improvement: a prospective cohort study in France (PERSICOR).
    Int J Infect Dis. 2023 Dec 21:S1201-9712(23)00798.
    PubMed     Abstract available


  177. SILI U MD, PHD, Tekin A MD, Bilgin H MD, MPH, Khan SA MD, et al
    Early empiric antibiotic use in COVID-19 patients: results from the international VIRUS registry.
    Int J Infect Dis. 2023 Dec 19:S1201-9712(23)00810.
    PubMed     Abstract available


  178. MICHAEL F, Mirambo MM, Misinzo G, Minzi O, et al
    Trends of measles in Tanzania: a five-year review of case-based surveillance data, 2018-2022.
    Int J Infect Dis. 2023 Dec 18:S1201-9712(23)00809.
    PubMed     Abstract available


  179. TICONA JPA, Xiao M, Li D, Nery N Jr, et al
    Extensive transmission of SARS-CoV-2 BQ.1* variant in a population with high levels of hybrid immunity: A prevalence survey.
    Int J Infect Dis. 2023 Dec 7:S1201-9712(23)00801.
    PubMed     Abstract available


  180. JUNYONG M, Wang Y, Liu J, Wu Y, et al
    Impact of perioperative SARS-CoV-2 Omicron infection on postoperative complications in liver cancer hepatectomy: A single-center matched study.
    Int J Infect Dis. 2023 Dec 6:S1201-9712(23)00803.
    PubMed     Abstract available


  181. SANTOS CAD, Paula AP, Filho GGF, Alves MM, et al
    Developmental impairment in children exposed during pregnancy to maternal SARS-COV2: A Brazilian cohort study.
    Int J Infect Dis. 2023 Dec 5:S1201-9712(23)00802.
    PubMed     Abstract available


  182. FINSTERER J, Scorza FA
    The frequency of SARS-CoV-2 infection/vaccination-related chorea depends on the inclusion/exclusion criteria.
    Int J Infect Dis. 2023;137:161.
    PubMed    


  183. ROSCA EC, Bilavu R, Cornea A, Simu M, et al
    The frequency of SARS-CoV-2 infection/vaccination-related chorea depends on the inclusion/exclusion criteria - author's reply.
    Int J Infect Dis. 2023;137:159-160.
    PubMed    


  184. BANDA L, Ho A, Kasenda S, Read JM, et al
    Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study.
    Int J Infect Dis. 2023;137:118-125.
    PubMed     Abstract available


    November 2023
  185. FLORES-GONZALEZ J, Chavez-Galan L, Falfan-Valencia R, Roldan IB, et al
    Variant rs4986790 of TLR4 affects the signaling and induces cell dysfunction in severe COVID-19 patients.
    Int J Infect Dis. 2023 Nov 27:S1201-9712(23)00793.
    PubMed     Abstract available


  186. YOSHIMURA M, Sakamoto A, Ozuru R, Kurihara Y, et al
    The appearance of anti-spike RBD IgG4 responses after repetitive immunization with mRNA-based COVID-19 vaccines.
    Int J Infect Dis. 2023 Nov 27:S1201-9712(23)00789.
    PubMed     Abstract available


  187. MOSTAGHIM A, Minkove S, Aguilar-Company J, Ruiz-Camps I, et al
    Prior immune checkpoint inhibitor (ICI) therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry.
    Int J Infect Dis. 2023 Nov 27:S1201-9712(23)00782.
    PubMed     Abstract available


  188. TANDLER C, Heitmann JS, Michel TM, Marconato M, et al
    Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adults.
    Int J Infect Dis. 2023 Nov 26:S1201-9712(23)00770.
    PubMed     Abstract available


  189. YANG X, Zhang J, Liu Z, Chen S, et al
    COVID-19 breakthrough infections among people with and without HIV: a statewide cohort analysis.
    Int J Infect Dis. 2023 Nov 25:S1201-9712(23)00790.
    PubMed     Abstract available


  190. HARRIES M, Jaeger VK, Rodiah I, Hassenstein MJ, et al
    Bridging the gap - estimation of 2022/2023 SARS-CoV-2 healthcare burden in Germany based on multidimensional data from a rapid epidemic panel.
    Int J Infect Dis. 2023 Nov 24:S1201-9712(23)00776.
    PubMed     Abstract available


  191. NAVARATNAM AM, O'Callaghan C, Beale S, Nguyen V, et al
    Eyeglasses and risk of COVID-19 transmission - analysis of the Virus Watch Community Cohort study.
    Int J Infect Dis. 2023 Nov 24:S1201-9712(23)00759.
    PubMed     Abstract available


  192. NGUYEN TTN, Choo EM, Nakamura Y, Suzuki R, et al
    Pre-existing cross-reactive neutralizing activity against SARS-CoV-2 and seasonal coronaviruses prior to the COVID-19 pandemic (2014-2019) with limited immunity against recent emerging SARS-CoV-2 variants, Vietnam.
    Int J Infect Dis. 2023 Nov 18:S1201-9712(23)00769.
    PubMed     Abstract available


  193. LI Y, Wu Z, Yan Y, Shi Y, et al
    Prevalence of respiratory viruses among hospitalized children with lower respiratory tract infections during the COVID-19 pandemic in Wuhan, China.
    Int J Infect Dis. 2023 Nov 18:S1201-9712(23)00780.
    PubMed     Abstract available


  194. BELLERBA F, Bardeck N, Boehm M, D'Ecclesiis O, et al
    SARS-CoV-2 trends in Italy, Germany and Portugal and school opening during the period of Omicron variant dominance: a quasi-experimental study.
    Int J Infect Dis. 2023 Nov 11:S1201-9712(23)00763.
    PubMed     Abstract available


  195. CHOGA WT, Kurusa Gasenna GK, San JE, Ookame T, et al
    Rapid dynamic changes of FL.2 variant: a case report of COVID-19 breakthrough infection.
    Int J Infect Dis. 2023 Nov 10:S1201-9712(23)00772.
    PubMed     Abstract available


  196. DALLMEYER LK, Schuz ML, Fragkou PC, Omony J, et al
    Epidemiology of respiratory viruses among children during the SARS-CoV-2 pandemic: A systematic review and meta-analysis.
    Int J Infect Dis. 2023 Nov 9:S1201-9712(23)00761.
    PubMed     Abstract available


  197. LOVELL JF, Miura K, Baik YO, Lee C, et al
    One-year Antibody Durability Induced by EuCorVac-19, a Liposome-Displayed COVID-19 RBD Subunit Vaccine, in Healthy Korean Subjects.
    Int J Infect Dis. 2023 Nov 7:S1201-9712(23)00765.
    PubMed     Abstract available


  198. LEE IT, Lin PJ, Yen HH
    Pediatric Neuroimaging Findings and Clinical Presentations of COVID-19: A Systematic Review.
    Int J Infect Dis. 2023 Nov 7:S1201-9712(23)00767.
    PubMed     Abstract available


    October 2023
  199. AGERGAARD J, Gunst JD, Schiottz-Christensen B, Ostergaard L, et al
    Long-term Prognosis at 1.5 years after Infection with Wild-type strain of SARS-CoV-2 and Alpha, Delta, as well as Omicron Variants.
    Int J Infect Dis. 2023 Oct 29:S1201-9712(23)00760.
    PubMed     Abstract available


  200. ROSSI G, Salmanton-Garcia J, Cattaneo C, Marchesi F, et al
    Age, Successive Waves, Immunization, and Mortality in Elderly COVID-19 Haematological Patients: EPICOVIDEHA Findings.
    Int J Infect Dis. 2023 Oct 18:S1201-9712(23)00749.
    PubMed     Abstract available


  201. RAVLO E, Ianevski A, Starheim E, Wang W, et al
    Boosted production of antibodies which neutralized different SARS-CoV-2 variants in a COVID-19 convalescent following mRNA vaccination - a case study.
    Int J Infect Dis. 2023 Oct 16:S1201-9712(23)00748.
    PubMed     Abstract available


  202. SHARMA A, Gupta B, Petersen E, Lee SS, et al
    Enhancing preparedness for reducing transmission and globalisation of Antimicrobial Resistance at the Ardh Kumbh Mela 2025, the world's largest recurring religious mass gathering.
    Int J Infect Dis. 2023 Oct 16:S1201-9712(23)00751.
    PubMed    


  203. BERG J, Thies-Lagergren L, Svedenkrans J, Samkutty J, et al
    Umbilical cord clamping in the early phases of the COVID-19 era - A systematic review and meta-analysis of reported practice and recommendations in guidelines.
    Int J Infect Dis. 2023 Oct 13:S1201-9712(23)00747.
    PubMed     Abstract available


  204. XU Y, Chen H, Wang B, Zhu X, et al
    Immunogenicity and safety of concomitant administration of the sabin-strain-based inactivated poliovirus vaccine, the diphtheria-tetanus-acellular pertussis vaccine and measles-mumps-rubella vaccine to healthy infants aged 18 months in China.
    Int J Infect Dis. 2023 Oct 11:S1201-9712(23)00743.
    PubMed     Abstract available


  205. HEJAZI NS, Shen X, Carpp LN, Benkeser D, et al
    Stochastic Interventional Approach to Assessing Immune Correlates of Protection: Application to the COVE mRNA-1273 Vaccine Trial.
    Int J Infect Dis. 2023 Oct 9:S1201-9712(23)00727.
    PubMed     Abstract available


  206. SCHUZ ML, Dallmeyer L, Fragkou PC, Omony J, et al
    Global prevalence of respiratory virus infections in adults and adolescents during the COVID-19 pandemic: A systematic review and meta-analysis.
    Int J Infect Dis. 2023 Oct 6:S1201-9712(23)00738.
    PubMed     Abstract available


  207. INABA M, Miyake Y, Yasuda K
    Secondary household transmission of SARS-CoV-2: A case-control study on factors associated with reduced transmission risk.
    Int J Infect Dis. 2023 Oct 1:S1201-9712(23)00733.
    PubMed     Abstract available


  208. GONCALVES YMP, de Assuncao TSF, de Sousa MAD, Ferreira LM Junior, et al
    Progressive multifocal leukoencephalopathy triggered by COVID-19 in a previously asymptomatic person living with undiagnosed HIV infection.
    Int J Infect Dis. 2023 Oct 1:S1201-9712(23)00730.
    PubMed     Abstract available


    September 2023
  209. FOCOSI D, Maggi F, D'Abramo A, Nicastri E, et al
    Antiviral combination therapies for persistent COVID-19 in immunocompromised patients.
    Int J Infect Dis. 2023 Sep 29:S1201-9712(23)00734.
    PubMed     Abstract available


  210. LAI MY, Bukhari FDM, Zulkefli NZ, Ismail I, et al
    Corrigendum to "Colorimetric detection of SARS-CoV-2 by uracil-DNA glycosylase (UDG) reverse transcription loop-mediated isothermal amplification (RT-LAMP)" [International Journal of Infectious Diseases 120 (2023) Pages 132-134].
    Int J Infect Dis. 2023;136:91.
    PubMed    


  211. WONG HM, Mun CH, Loke WK, Lim WQ, et al
    Moist heat as a promising method to decontaminate N95 masks - a large scale clinical study comparing four decontamination modalities: moist heat, steam, ultraviolet-C irradiation and hydrogen peroxide plasma.
    Int J Infect Dis. 2023 Sep 25:S1201-9712(23)00729.
    PubMed     Abstract available


  212. CASTRO-RODRIGUEZ B, Morales-Jadan D, Viteri-Davila C, Rodriguez AS, et al
    "The fake positive results of COVID-19 rapid antigen tests with the use of beverages vary between brands of test kits".
    Int J Infect Dis. 2023 Sep 22:S1201-9712(23)00718.
    PubMed    


  213. GIACOMELLI A, Gagliardini R, Tavelli A, De Benedittis S, et al
    Risk of COVID-19 in-hospital mortality in people living with HIV compared to general population according to age and CD4 strata: data from the Icona network.
    Int J Infect Dis. 2023 Sep 21:S1201-9712(23)00728.
    PubMed     Abstract available


  214. PREGER A, Wei R, Berg B, Golomb BA, et al
    Covid-19-Associated Rhabdomyolysis: A Scoping Review.
    Int J Infect Dis. 2023 Sep 18:S1201-9712(23)00713.
    PubMed     Abstract available


  215. KAYA H, Tani H, Inasaki N, Yazawa S, et al
    Virus evolution and reduced viral viability during treatment of persistent COVID-19 Omicron BA.5 infection in an immunocompromised host.
    Int J Infect Dis. 2023 Sep 16:S1201-9712(23)00721.
    PubMed     Abstract available


  216. HUJAMBERDIEVA LM, Chimed-Ochir O, Yumiya Y, Tanaka J, et al
    Relationship between clinical symptom profiles and COVID-19 infection status during delta-dominant period versus omicron-dominant period - analysis of real-world data collected in Hiroshima Prefecture, Japan.
    Int J Infect Dis. 2023 Sep 15:S1201-9712(23)00717.
    PubMed     Abstract available


  217. NAYYERABADI M, Fourcade L, Joshi SA, Chandrasekaran P, et al
    Vaccination after developing long COVID: impact on clinical presentation, viral persistence and immune responses.
    Int J Infect Dis. 2023 Sep 15:S1201-9712(23)00720.
    PubMed     Abstract available


  218. CHEMAITELLY H, Faust JS, Krumholz HM, Ayoub HH, et al
    Short- and longer-term all-cause mortality among SARS-CoV-2- infected individuals and the pull-forward phenomenon in Qatar: A national cohort study.
    Int J Infect Dis. 2023 Sep 15:S1201-9712(23)00719.
    PubMed     Abstract available


  219. SSALI I, Mugaba S, Watelo AK, Bemanzi J, et al
    Spike Protein is a key target for stronger and more persistent T-Cell Responses - A study of mild and asymptomatic SARS-CoV-2 Infection.
    Int J Infect Dis. 2023 Sep 6:S1201-9712(23)00714.
    PubMed     Abstract available


  220. MIDDELKOOP K, Stewart J, Walker N, Delport C, et al
    Vitamin D supplementation to prevent tuberculosis infection in South African schoolchildren: multicenter phase 3 double-blind randomized placebo-controlled trial (ViDiKids).
    Int J Infect Dis. 2023;134:63-70.
    PubMed     Abstract available


  221. FAN Y, Gao R, Shang Y, Tian X, et al
    Presence of SARS-CoV-2 in middle ear fluid and characterization of otitis media with effusion in COVID-19 patients.
    Int J Infect Dis. 2023 Sep 1:S1201-9712(23)00709.
    PubMed     Abstract available


    August 2023
  222. HAUTEFORT C, Corre A, Poillon G, Jourdaine C, et al
    Local budesonide therapy in the management of persistent hyposmia in suspected non-severe COVID-19 patients: Results of a randomized controlled trial.
    Int J Infect Dis. 2023 Aug 29:S1201-9712(23)00707.
    PubMed     Abstract available


  223. YAN X, Li K, Lei Z, Luo J, et al
    Prevalence and associated outcomes of co-infection between SARS-CoV-2 and influenza: a systematic review and meta-analysis.
    Int J Infect Dis. 2023 Aug 28:S1201-9712(23)00705.
    PubMed     Abstract available


  224. DIEXER S, Klee B, Gottschick C, Xu C, et al
    Association between Virus Variants, Vaccination, Previous Infections, and Post COVID-19 Risk.
    Int J Infect Dis. 2023 Aug 25:S1201-9712(23)00702.
    PubMed     Abstract available


  225. MI Y, Huang L, Liu J, Chao H, et al
    High-altitude Resident Pulmonary Edema Induced by SARS-CoV-2 Infection in Children - A Case Series.
    Int J Infect Dis. 2023 Aug 21:S1201-9712(23)00700.
    PubMed     Abstract available


  226. JANHA RE, Bah A, Jah H, Touray F, et al
    SARS-CoV-2 seroprevalence in pregnant women during the first three COVID-19 waves in The Gambia.
    Int J Infect Dis. 2023 Aug 14:S1201-9712(23)00697.
    PubMed     Abstract available


  227. EDELSTEIN M, Beiruti KW, Ben-Amram H, Beer N, et al
    Vaccine-induced and hybrid immunity to SARS-CoV-2 after three or four doses of BNT162b2 - results from 22 months follow-up of a healthcare workers cohort, Israel, 2020-2022.
    Int J Infect Dis. 2023 Aug 10:S1201-9712(23)00694.
    PubMed     Abstract available


  228. CHAE C, Kim RK, Jang EJ, Shim JA, et al
    Comparing the Effectiveness of Bivalent and Monovalent COVID-19 Vaccines against COVID-19 Infection during the Winter Season of 2022-2023: A Real-World Retrospective Observational Matched Cohort Study in the Republic of Korea.
    Int J Infect Dis. 2023 Aug 10:S1201-9712(23)00695.
    PubMed     Abstract available


  229. LOW EV, Pathmanathan MD, Chidambaram SK, Kim WR, et al
    Real world nirmatrelvir-ritonavir outpatient treatment in reducing hospitalization for high-risk COVID-19 patients during Omicron BA.4, BA.5 and XBB subvariants dominance in Malaysia: A retrospective cohort study.
    Int J Infect Dis. 2023 Aug 9:S1201-9712(23)00688.
    PubMed     Abstract available


  230. WAILI BA, Yazidi LA, Hashami HA, Gheilani MA, et al
    A comparative study of SARS-CoV-2 and common human coronavirus infections among children presenting to tertiary care in Oman.
    Int J Infect Dis. 2023 Aug 9:S1201-9712(23)00690.
    PubMed     Abstract available


  231. DOMNICH A, Orsi A, Ricucci V, De Pace V, et al
    Real-world performance of SARS-CoV-2 rapid antigen testing through the Alpha-, Delta- and Omicron-dominant waves of the COVID-19 pandemic.
    Int J Infect Dis. 2023 Aug 2:S1201-9712(23)00679.
    PubMed     Abstract available


  232. TANAKA H, Namkoong H, Chubachi S, Irie S, et al
    Clinical characteristics of patients with COVID-19 harboring detectable intracellular SARS-CoV-2 RNA in peripheral blood cells.
    Int J Infect Dis. 2023 Aug 2:S1201-9712(23)00680.
    PubMed     Abstract available


    July 2023
  233. AGUARELES J, Villares-Fernandez P, Carralon-Gonzalez MM, Forne C, et al
    Outcomes and clinical characteristics of the compassionate use of plitidepsin for immunocompromised adult patients with COVID-19.
    Int J Infect Dis. 2023 Jul 21:S1201-9712(23)00661.
    PubMed     Abstract available


  234. FANG X, Lu K, Sun S, Zhang H, et al
    Infection caused by Cupriavidus gilardii in a convalescent COVID-19 patient.
    Int J Infect Dis. 2023 Jul 20:S1201-9712(23)00663.
    PubMed     Abstract available


  235. LIANG W, Lv H, Chen C, Sun Y, et al
    Lack of neutralizing antibodies against influenza A viruses in adults during the 2022/2023 winter season - a serological study using retrospective samples collected in Hong Kong.
    Int J Infect Dis. 2023 Jul 20:S1201-9712(23)00659.
    PubMed     Abstract available


  236. TIAN T, Fu L, Lu Z, Wu X, et al
    Changes in HPV prevalence, incidence, and clearance among MSM in Xinjiang, China after implementation of nonpharmaceutical interventions to control COVID-19: An interrupted time series analysis.
    Int J Infect Dis. 2023 Jul 13:S1201-9712(23)00654.
    PubMed     Abstract available


  237. HOWARD LM, Huang X, Chen W, Liu Y, et al
    Association between nasopharyngeal colonization with multiple pneumococcal serotypes and total pneumococcal colonization density in young Peruvian children.
    Int J Infect Dis. 2023 Jul 12:S1201-9712(23)00653.
    PubMed     Abstract available


  238. ROSCA EC, Bilavu R, Cornea A, Simu M, et al
    Chorea following SARS-CoV-2 infection and vaccination: a systematic review of reported cases.
    Int J Infect Dis. 2023 Jul 7:S1201-9712(23)00652.
    PubMed     Abstract available


  239. PUYAT JH, Fowokan A, Wilton J, Janjua NZ, et al
    Risk of COVID-19 Hospitalization in People Living with HIV and HIV-Negative Individuals and the Role of COVID-19 Vaccination: A Retrospective Cohort Study.
    Int J Infect Dis. 2023 Jul 5:S1201-9712(23)00650.
    PubMed     Abstract available


  240. COWAN J, Amson A, Christofides A, Chagla Z, et al
    Monoclonal antibodies as COVID-19 prophylaxis therapy in immunocompromised patient populations.
    Int J Infect Dis. 2023 Jul 1:S1201-9712(23)00645.
    PubMed     Abstract available


    June 2023
  241. SIRIPONGBOONSITTI T, Ungtrakul T, Tawinprai K, Nimmol T, et al
    Efficacy of Combination Therapy of Fluvoxamine and Favipiravir versus Favipiravir Monotherapy to Prevent Severe COVID-19 among Mild to Moderate COVID-19 Patients: Open-label Randomized Controlled Trial (EFFaCo Study).
    Int J Infect Dis. 2023 Jun 29:S1201-9712(23)00641.
    PubMed     Abstract available


  242. BONNA AS, Pavel SR, Mehjabin T, Ali M, et al
    Dengue in Bangladesh.
    Int J Infect Dis. 2023 Jun 29:S1201-9712(23)00644.
    PubMed     Abstract available


  243. MAEDA M, Murata F, Fukuda H
    Effect of COVID-19 Vaccination on Household Transmission of SARS-CoV-2 in the Omicron Era: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study.
    Int J Infect Dis. 2023 Jun 23:S1201-9712(23)00642.
    PubMed     Abstract available


  244. KANG JM, Kang M, Kim YE, Choi Y, et al
    Severe coronavirus disease 2019 in pediatric solid organ transplant recipients: Big data convergence study in Korea (K-COV-N cohort).
    Int J Infect Dis. 2023 Jun 21:S1201-9712(23)00640.
    PubMed     Abstract available


  245. JIAO Y, Zhao J, Wang Z, Chen X, et al
    How do Orphan Disease Patients Live Under the Pandemic of Omicron Variant? - A Nationwide Survey of Spinal Muscular Atrophy Patients in China.
    Int J Infect Dis. 2023 Jun 21:S1201-9712(23)00639.
    PubMed     Abstract available


  246. VERGORI A, Matusali G, Lepri AC, Cimini E, et al
    Neutralizing activity and T Cell response after bivalent fifth dose of mRNA vaccine in person living with HIV.
    Int J Infect Dis. 2023 Jun 19:S1201-9712(23)00632.
    PubMed     Abstract available


  247. IOANNIDIS JPA, Contopoulos-Ioannidis DG
    Pre-pandemic cross-reactive humoral immunity to SARS-CoV-2 in Africa: systematic review and meta-analysis.
    Int J Infect Dis. 2023 Jun 14:S1201-9712(23)00631.
    PubMed     Abstract available


  248. MORENO-TORRES V, Martinez-Urbistondo M, Calderon-Parra J, Patricia Mills, et al
    COVID-19 in hospitalized solid organ transplant recipients in a nationwide registry study.
    Int J Infect Dis. 2023 Jun 13:S1201-9712(23)00629.
    PubMed     Abstract available


  249. COHEN PJF, Rybak DA, Werner DA, Kochert DF, et al
    Surveillance of non-invasive group A Streptococcus infections in French ambulatory pediatrics before and during the COVID-19 pandemic: a prospective multicenter study from 2018 to 2022.
    Int J Infect Dis. 2023 Jun 6:S1201-9712(23)00622.
    PubMed     Abstract available


  250. PITA-MARTINEZ C, Perez-Garcia F, Berdices AV, Martin-Vicente M, et al
    A deficient immune response to SARS-CoV-2 in the nasopharynx is associated with severe COVID-19 pneumonia.
    Int J Infect Dis. 2023 Jun 6:S1201-9712(23)00623.
    PubMed     Abstract available


    May 2023
  251. ZHANG R, Wen J, Wu K, Lin S, et al
    Influenza-associated neurologic complications in children from an H3N2 outbreak in Shenzhen, China during COVID-19 lockdown.
    Int J Infect Dis. 2023 May 30:S1201-9712(23)00616.
    PubMed     Abstract available


  252. BLANQUART F, Abad C, Ambroise J, Bernard M, et al
    Temporal, age and geographical variation in vaccine efficacy against infection by the Delta and Omicron variants in the community in France, December 2021 to March 2022.
    Int J Infect Dis. 2023 May 12:S1201-9712(23)00539.
    PubMed     Abstract available


  253. SERVIER C, Porcher R, Pane I, Ravaud P, et al
    Trajectories of the evolution of post COVID-19 condition, up to two years after symptoms onset.
    Int J Infect Dis. 2023 May 12:S1201-9712(23)00558.
    PubMed     Abstract available


  254. HUI DS, Yung L, Chan KK, Ng SS, et al
    Risk of air and surface contamination during application of different non-invasive respiratory support for patients with COVID-19.
    Int J Infect Dis. 2023 May 12:S1201-9712(23)00560.
    PubMed     Abstract available


  255. MARANGONI D, Antonello RM, Coppi M, Palazzo M, et al
    Combination regimen of nirmatrelvir/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: a case report and a scoping review of the literature.
    Int J Infect Dis. 2023 May 5:S1201-9712(23)00546.
    PubMed     Abstract available


  256. KUODI P, Gorelik Y, Gausi B, Bernstine T, et al
    Characterisation of post-COVID syndromes by symptom cluster and time period up to 12 months post-infection: A systematic review and meta-analysis.
    Int J Infect Dis. 2023 May 5:S1201-9712(23)00549.
    PubMed     Abstract available


  257. ZENS KD, Llanas-Cornejo D, Menges D, Fehr JS, et al
    Longitudinal Humoral and Cell-Mediated Immune Responses in a Population-Based Cohort in Zurich, Switzerland from March to June 2022 - Evidence for Protection against Omicron SARS-CoV-2 Infection by Neutralizing Antibodies and Spike-specific T cells.
    Int J Infect Dis. 2023 May 4:S1201-9712(23)00538.
    PubMed     Abstract available


  258. ORLANDO SA, Calderon JL, Leon-Sosa A, Patino L, et al
    Corrigendum to ";SARS-CoV-2 transmission from infected owner to household dogs and cats is associated with food sharing" [International Journal of Infectious Diseases, 122 (2022) Pages 295-299].
    Int J Infect Dis. 2023;130:214-215.
    PubMed    


  259. ALBERTO-ORLANDO S, Garcia-Bereguiain MA
    Concerns regarding risk factors for SARS-CoV-2 transmission to pets: author's reply.
    Int J Infect Dis. 2023;130:212-213.
    PubMed    


  260. WEESE S
    Concerns regarding risk factors for SARS-CoV-2 transmission to pets.
    Int J Infect Dis. 2023;130:211.
    PubMed    


  261. GOLETTI D, Al-Abri S, Migliori GB, Coler R, et al
    World Tuberculosis Day 2023 theme "Yes! We Can End TB!".
    Int J Infect Dis. 2023;130 Suppl 1:S1-S3.
    PubMed     Abstract available


  262. GOLETTI D, Al-Abri S, Migliori GB, Coler R, et al
    World Tuberculosis Day 2023 theme "Yes! We Can End TB!".
    Int J Infect Dis. 2023;130 Suppl 1:S1-S3.
    PubMed     Abstract available


  263. GOLETTI D, Al-Abri S, Migliori GB, Coler R, et al
    World Tuberculosis Day 2023 theme "Yes! We Can End TB!".
    Int J Infect Dis. 2023;130 Suppl 1:S1-S3.
    PubMed     Abstract available


  264. GOLETTI D, Al-Abri S, Migliori GB, Coler R, et al
    World Tuberculosis Day 2023 theme "Yes! We Can End TB!".
    Int J Infect Dis. 2023;130 Suppl 1:S1-S3.
    PubMed     Abstract available


    April 2023
  265. TANAKA H, Chubachi S, Asakura T, Namkoong H, et al
    Characteristics and Clinical Effectiveness of COVID-19 Vaccination in Hospitalized Patients in Omicron-dominated Epidemic Wave - A Nationwide Study in Japan.
    Int J Infect Dis. 2023 Apr 20:S1201-9712(23)00529.
    PubMed     Abstract available


  266. HUIBERTS AJ, de Gier B, Hoeve CE, de Melker HE, et al
    Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection in the Netherlands from 12 July 2021 to 6 June 2022: a prospective cohort study.
    Int J Infect Dis. 2023 Apr 20:S1201-9712(23)00534.
    PubMed     Abstract available


  267. MOLINA KC, Kennerley V, Beaty LE, Bennett TD, et al
    Real-World Evaluation of Bebtelovimab Effectiveness During the Period of COVID-19 Omicron Variants including BA.4/BA.5.
    Int J Infect Dis. 2023 Apr 16:S1201-9712(23)00525.
    PubMed     Abstract available


  268. COHEN D, Izak M, Stoyanov E, Mandelboim M, et al
    Predictors of reinfection with pre-Omicron and Omicron variants of concern among individuals who recovered from COVID-19 in the first year of the pandemic.
    Int J Infect Dis. 2023 Apr 16:S1201-9712(23)00526.
    PubMed     Abstract available


  269. LEE VH, Chan SK, Tam YH, Chau TC, et al
    Predictive factors of delayed viral clearance of asymptomatic omicron-related COVID-19 screened positive in cancer patients receiving active anti-cancer treatment.
    Int J Infect Dis. 2023 Apr 16:S1201-9712(23)00527.
    PubMed     Abstract available


  270. YIN S, Ren J, Xue J, Li P, et al
    Disparities in COVID-19 clinical studies from high-income and low-and middle-income countries.
    Int J Infect Dis. 2023 Apr 15:S1201-9712(23)00522.
    PubMed     Abstract available


  271. BUTT AA, Guerrero MD, Canlas EB, Al-Dwairi H, et al
    Immediate and Contributory Causes of Death in Patients Hospitalized with COVID-19.
    Int J Infect Dis. 2023 Apr 13:S1201-9712(23)00514.
    PubMed     Abstract available


  272. BRYNILDSRUD OB, Watle SV, Alfsnes K, Caugant DA, et al
    Invasive meningococcal disease in Norway in the two decades prior to the COVID-19 pandemic.
    Int J Infect Dis. 2023 Apr 6:S1201-9712(23)00136.
    PubMed     Abstract available


    March 2023
  273. VON BARTHELD CS, Wang L
    The prevalence of olfactory dysfunction with Omicron has decreased in Asia, similar to Western countries.
    Int J Infect Dis. 2023 Mar 30:S1201-9712(23)00121.
    PubMed    


  274. LAWAL BJ, Gallagher KE, Kitonsa J, Tindanbil D, et al
    Prevalence of IgG and IgM to SARS-CoV-2 and other human coronaviruses in The Democratic Republic of Congo, Sierra Leone and Uganda: A Longitudinal Study.
    Int J Infect Dis. 2023 Mar 29:S1201-9712(23)00128.
    PubMed     Abstract available


  275. AZHAR EI, Velavan TP, Rungsung I, Traore T, et al
    Middle East Respiratory Syndrome Coronavirus (MERS-CoV) - a ten-year (2012-2022) global analysis of human and camel infections, genomic sequences, lineages, and geographical origins.
    Int J Infect Dis. 2023 Mar 28:S1201-9712(23)00125.
    PubMed     Abstract available


  276. BODNER K, Irvine MA, Kwong JC, Mishra S, et al
    Observed negative vaccine effectiveness could be the canary in the coal mine for biases in observational Covid-19 studies.
    Int J Infect Dis. 2023 Mar 27:S1201-9712(23)00102.
    PubMed     Abstract available


  277. GUO Y, Wu S, Ye W, Zhao Z, et al
    Impact of public health and social measures on contact dynamics during a SARS-CoV-2 Omicron variant outbreak in Quanzhou, China, March to April 2022.
    Int J Infect Dis. 2023 Mar 24:S1201-9712(23)00104.
    PubMed     Abstract available


  278. NAVEED Z, Li J, Naus M, Garcia HAV, et al
    A Population-Based Assessment of Myocarditis Following mRNA COVID-19 booster Vaccination Among Adult Recipients.
    Int J Infect Dis. 2023 Mar 24:S1201-9712(23)00106.
    PubMed     Abstract available


  279. LARSEN SE, Baldwin SL, Coler RN
    TB Vaccines Update: is an RNA-based vaccine feasible for TB?
    Int J Infect Dis. 2023 Mar 22:S1201-9712(23)00114.
    PubMed     Abstract available


  280. ZINSZER K, Charland K, Pierce L, Saucier A, et al
    Pre-Omicron seroprevalence, seroconversion, and seroreversion of infection-induced SARS-CoV-2 antibodies among a cohort of children and teenagers in Montreal, Canada.
    Int J Infect Dis. 2023 Mar 22:S1201-9712(23)00115.
    PubMed     Abstract available


  281. TAN KS, Ong SWX, Koh MH, Tay DJW, et al
    SARS-CoV-2 Omicron variant shedding during respiratory activities.
    Int J Infect Dis. 2023 Mar 20:S1201-9712(23)00109.
    PubMed     Abstract available


  282. WU J, Shi X, Tao B, Zhan Y, et al
    Inactivated COVID-19 vaccines booster dose shortened the viral shedding time of patients infected with the Omicron variant BA.2.
    Int J Infect Dis. 2023 Mar 20:S1201-9712(23)00107.
    PubMed     Abstract available


  283. DAVIDO B, Jaffal K, Gault E, Bourlet S, et al
    Back to the Future of Viruses: A Case of Triple Coinfection caused by RSV, HCov-OC43 and Rhinovirus.
    Int J Infect Dis. 2023 Mar 20:S1201-9712(23)00101.
    PubMed     Abstract available


  284. NAJAFI-FARD S, Aiello A, Navarra A, Cuzzi G, et al
    Characterization of the immune impairment of tuberculosis and COVID-19 coinfected patients.
    Int J Infect Dis. 2023 Mar 19:S1201-9712(23)00099.
    PubMed     Abstract available


  285. NEVOLA R, Feola G, Ruocco R, Russo A, et al
    Mortality and risk factors of vaccinated and unvaccinated COVID-19 frail patients treated with anti-SARS-CoV-2 monoclonal antibodies. A real-world study.
    Int J Infect Dis. 2023 Mar 19:S1201-9712(23)00110.
    PubMed     Abstract available


  286. CHILLON TS, Demircan K, Weiss G, Minich WB, et al
    Detection of antibodies to SARS-CoV-2 after vaccination in seminal plasma and their association to sperm parameters.
    Int J Infect Dis. 2023 Mar 16:S1201-9712(23)00095.
    PubMed     Abstract available


  287. HAMA HO, Chenal T, Pible O, Miotello G, et al
    An ancient coronavirus from individuals in France, circa 16(th) century.
    Int J Infect Dis. 2023 Mar 14:S1201-9712(23)00093.
    PubMed     Abstract available


  288. ZANNOLI S, Brandolini M, Marino MM, Denicolo A, et al
    SARS-CoV-2 Co-Infection in Immunocompromised Host Leads to Generation of Recombinant Strain.
    Int J Infect Dis. 2023 Mar 14:S1201-9712(23)00088.
    PubMed     Abstract available


  289. MA Y, Gu Y, Shan Z, Huang Y, et al
    Safety and efficacy of inactivated COVID-19 vaccines in women vaccinated during the first trimester of pregnancy.
    Int J Infect Dis. 2023 Mar 14:S1201-9712(23)00094.
    PubMed     Abstract available


  290. WANG X, Tang Q, Li H, Jiang H, et al
    Autoantibodies against type I interferons in COVID-19 infection: a systematic review and meta-analysis.
    Int J Infect Dis. 2023 Mar 10:S1201-9712(23)00087.
    PubMed     Abstract available


  291. HOUBEN F, den Heijer CD, Dukers-Muijrers NH, Daamen AM, et al
    Facility- and ward-level factors associated with SARS-CoV-2 outbreaks among residents in long-term care facilities: a retrospective cohort study.
    Int J Infect Dis. 2023 Mar 9:S1201-9712(23)00082.
    PubMed     Abstract available


  292. THONG PM, Chong HT, Chang AJW, Ong CWM, et al
    COVID-19, the escalation of diabetes and the repercussions on Tuberculosis.
    Int J Infect Dis. 2023 Mar 8:S1201-9712(23)00055.
    PubMed     Abstract available


  293. NALUNJOGI J, Mucching-Toscano S, Sibomana JP, Centis R, et al
    Impact of COVID-19 on diagnosis of TB, MDR-TB and on mortality in 11 countries in Europe, Northern America and Australia. A Global Tuberculosis Network study.
    Int J Infect Dis. 2023 Mar 7:S1201-9712(23)00076.
    PubMed     Abstract available


  294. VENETI L, Berild JD, Watle SV, Starrfelt J, et al
    Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022.
    Int J Infect Dis. 2023 Mar 7:S1201-9712(23)00080.
    PubMed     Abstract available


  295. EVANS TS, Tan CW, Aung O, Phyu S, et al
    Exposure to diverse sarbecoviruses indicates frequent zoonotic spillover in human communities interacting with wildlife.
    Int J Infect Dis. 2023 Mar 2:S1201-9712(23)00064.
    PubMed     Abstract available


  296. VELAVAN TP, Ntoumi F, Kremsner PG, Lee SS, et al
    Emergence and geographic dominance of Omicron subvariants XBB/XBB.1.5 and BF.7 - the public health challenges.
    Int J Infect Dis. 2023;128:307-309.
    PubMed    


  297. ZILVER SJM, de Groot CJM, Grobben M, Remmelzwaal S, et al
    Vaccination from the early second trimester onwards gives a robust SARS-CoV-2 antibody response throughout pregnancy and provides antibodies for the neonate.
    Int J Infect Dis. 2023 Mar 1:S1201-9712(23)00071.
    PubMed     Abstract available


    February 2023
  298. KANG W, Yang P, Dang B, Zhang W, et al
    Dynamics of disease characteristics and viral RNA decay in patients with asymptomatic and mild infections during the Omicron wave in Shanghai, China: A retrospective cohort study.
    Int J Infect Dis. 2023 Feb 25:S1201-9712(23)00067.
    PubMed     Abstract available


  299. HOWARD-JONES AR, Arnott A, Draper J, Gall M, et al
    Emergent Omicron BR.2.1 Sublineage of SARS-CoV-2 in New South Wales, Australia: A Subvariant with High Fitness but Without Increased Disease Severity.
    Int J Infect Dis. 2023 Feb 24:S1201-9712(23)00068.
    PubMed     Abstract available


  300. SANTOS AP, Werneck GL, Dalvi APR, Dos Santos CC, et al
    The effect of BCG vaccination on infection and antibody levels against SARS-CoV-2 - The results of ProBCG: A Multicenter Randomized Clinical Trial in Brazil.
    Int J Infect Dis. 2023 Feb 23:S1201-9712(23)00065.
    PubMed     Abstract available


  301. CHANTASRISAWAD N, Techasaensiri C, Kosalaraksa P, Phongsamart W, et al
    The immunogenicity of an extended dosing interval of BNT162b2 against SARS-CoV-2 Omicron variant among healthy school-aged children, a randomized controlled trial.
    Int J Infect Dis. 2023 Feb 23:S1201-9712(23)00066.
    PubMed     Abstract available


  302. PEREIRA PD, Pires MC, Gomes VMR, Nogueira MCA, et al
    Clinical characteristics and outcomes of hospital-manifested COVID-19 among Brazilians.
    Int J Infect Dis. 2023 Feb 20:S1201-9712(23)00059.
    PubMed     Abstract available


  303. WU Y, Guo Z, Yuan J, Cao G, et al
    Duration of viable virus shedding and PCR positivity of the SARS-CoV-2 Omicron variant in upper respiratory tract: a systematic review and meta-analysis.
    Int J Infect Dis. 2023 Feb 17:S1201-9712(23)00057.
    PubMed     Abstract available


  304. VAIRA LA, De Riu G, Mayo-Yanez M, Gengler IM, et al
    Prevalence of chemosensitive disorders with Omicron infections and the possible impacts of vaccination.
    Int J Infect Dis. 2023 Feb 15:S1201-9712(23)00054.
    PubMed    


  305. BELLO-CHAVOLLA OY, Antonio-Villa NE, Valdes-Ferrer SI, Fermin-Martinez CA, et al
    Effectiveness of a nation-wide COVID-19 vaccination program in Mexico against symptomatic COVID-19, hospitalizations, and death: a retrospective analysis of national surveillance data.
    Int J Infect Dis. 2023 Feb 10:S1201-9712(23)00042.
    PubMed     Abstract available


  306. BANGAR S, Sonar P, Mane A, Sane S, et al
    Prevention of recurrence of bacterial vaginosis using lactobacilli-containing vaginal tablets among women with HIV: a randomized, placebo-controlled, double-blinded phase IV trial.
    Int J Infect Dis. 2023;129:197-204.
    PubMed     Abstract available


  307. DE CASTRO MV, Silva MVR, Oliveira LM, Gozzi-Silva SC, et al
    "Immunological evaluation of unvaccinated young patients with Turner Syndrome after COVID-19".
    Int J Infect Dis. 2023 Feb 7:S1201-9712(23)00044.
    PubMed     Abstract available


  308. SAITOH H, Sakai-Tagawa Y, Nagasawa S, Torimitsu S, et al
    High titers of infectious SARS-CoV-2 in COVID-19 corpses.
    Int J Infect Dis. 2023 Feb 6:S1201-9712(23)00047.
    PubMed     Abstract available


  309. SWETS MC, Moss RJ, Kor F, Hilarius D, et al
    A comparison of the effectiveness of different doses of tocilizumab and sarilumab in the treatment of severe COVID-19: a natural experiment due to drug shortages.
    Int J Infect Dis. 2023 Feb 2:S1201-9712(23)00041.
    PubMed     Abstract available


  310. LIU C, Lu J, Li P, Feng S, et al
    A Comparative study on epidemiological characteristics, transmissibility, and pathogenicity of three COVID-19 outbreaks caused by different variants.
    Int J Infect Dis. 2023 Feb 1:S1201-9712(23)00039.
    PubMed     Abstract available


  311. PATEL S, Truong GT, Rajan A, Creech Z, et al
    Discharge Disposition and Clinical Outcomes of Patients Hospitalized with COVID-19.
    Int J Infect Dis. 2023 Feb 1:S1201-9712(23)00040.
    PubMed     Abstract available


    January 2023
  312. BANKO A, Miljanovic D, Cirkovic A
    Systematic review with meta-analysis of active herpesvirus infections in patients with COVID-19: Old players on the new field.
    Int J Infect Dis. 2023 Jan 31:S1201-9712(23)00037.
    PubMed     Abstract available


  313. SEERY V, Raiden S, Penedo JMG, Borda M, et al
    Persistent symptoms after COVID-19 in children and adolescents from Argentina.
    Int J Infect Dis. 2023 Jan 31:S1201-9712(23)00033.
    PubMed     Abstract available


  314. LIU Y, Xu L, Piao X, Li H, et al
    Epidemiological, Clinical and Household Transmission Characteristics of Children and Adolescents Infected with SARS-CoV-2 Omicron Variant in Shanghai, China: a Retrospective Multicenter Observational Study.
    Int J Infect Dis. 2023 Jan 29:S1201-9712(23)00031.
    PubMed     Abstract available


  315. PETRONE D, Mateo-Urdiales A, Sacco C, Riccardo F, et al
    Reduction of the risk of severe COVID-19 due to Omicron compared to Delta variant in Italy (November 2021 - February 2022).
    Int J Infect Dis. 2023 Jan 25:S1201-9712(23)00027.
    PubMed     Abstract available


  316. WU S, Wang L, Dong J, Bao Y, et al
    The Dose- and Time-Dependent Effectiveness and Safety Associated with COVID-19 Vaccination During Pregnancy: A Systematic Review and Meta-analysis.
    Int J Infect Dis. 2023;128:335-46.
    PubMed     Abstract available


  317. ATEF S, Hosani FA, AbdelWareth L, Al-Rifai RH, et al
    Susceptibility to Reinfection with SARS-CoV-2 Virus Relative to Existing Antibody Concentrations and T cell Response.
    Int J Infect Dis. 2023 Jan 23:S1201-9712(23)00005.
    PubMed     Abstract available


  318. YAMAMOTO S, Matsuda K, Maeda K, Horii K, et al
    Neutralizing antibodies following three doses of BNT162b2 vaccine, breakthrough infection, and symptoms during the Omicron predominant wave.
    Int J Infect Dis. 2023 Jan 21:S1201-9712(23)00023.
    PubMed     Abstract available


  319. METCHURTCHLISHVILI R, Chkhartishvili N, Abutidze A, Endeladze M, et al
    Effect of remdesivir on mortality and the need for mechanical ventilation among hospitalized COVID-19 patients: real-world data from resource-limited country.
    Int J Infect Dis. 2023 Jan 20:S1201-9712(23)00022.
    PubMed     Abstract available


  320. HELLER M, Henrici C, Buttner J, Leube S, et al
    SARS-CoV-2 Neutralizing Antibody Therapies: Early retrospective cohort study of 26 hospitalized patients treated with Bamlanivimab or Casirivimab/Imdevimab.
    Int J Infect Dis. 2023 Jan 20:S1201-9712(23)00012.
    PubMed     Abstract available


  321. NAGGIE S, Milstone A, Castro M, Collins SP, et al
    Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: A randomized, multicenter, placebo-controlled trial (HERO-HCQ).
    Int J Infect Dis. 2023 Jan 19:S1201-9712(23)00019.
    PubMed     Abstract available


  322. NIYOMNAITHAM S, Jongkaewwattana A, Meesing A, Pinpathomrat N, et al
    Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 mRNA vaccine after two doses of CoronaVac vaccines against Delta and Omicron variants.
    Int J Infect Dis. 2023 Jan 19:S1201-9712(23)00021.
    PubMed     Abstract available


  323. SONG J, Jing Q, Zhu E, Liu Q, et al
    Alterations in smell or taste in individuals infected with SARS-CoV-2 during periods of Omicron variant dominance.
    Int J Infect Dis. 2023 Jan 16:S1201-9712(23)00017.
    PubMed     Abstract available


  324. HIRAE K, Hoshina T, Koga H
    Impact of COVID-19 pandemic on the epidemiology of other communicable diseases in Japan.
    Int J Infect Dis. 2023 Jan 12:S1201-9712(23)00013.
    PubMed     Abstract available


  325. CHEN SH, Wu JL, Liu YC, Yen TY, et al
    Differential clinical characteristics and performance of home antigen tests between parents and children following household transmission of SARS-CoV-2 during the Omicron variant pandemic.
    Int J Infect Dis. 2023 Jan 12:S1201-9712(23)00014.
    PubMed     Abstract available


  326. SANTOS VS, Allgayer MF, Kontogianni K, Rocha JE, et al
    Pooling of sputum samples to increase tuberculosis diagnostic capacity in Brazil during the COVID-19 pandemic.
    Int J Infect Dis. 2023 Jan 12:S1201-9712(23)00011.
    PubMed     Abstract available


  327. LIN SM, Lee CS, Huang AC, Chiu TH, et al
    Effects of Dexamethasone Use on Viral Clearance Among Patients with COVID-19: A Multicenter Cohort Study.
    Int J Infect Dis. 2023 Jan 12:S1201-9712(23)00010.
    PubMed     Abstract available


  328. NUCHNOI P, Piromtong P, Siribal S, Anansilp K, et al
    Applicability of a Colorimetric RT-LAMP Assay for SARS-CoV-2 Detection in High Exposure Risk Setting.
    Int J Infect Dis. 2023 Jan 12:S1201-9712(23)00009.
    PubMed     Abstract available


  329. AHSBERG J, Bjerrum S, Ganu VJ, Kwashie A, et al
    The in-hospital tuberculosis diagnostic cascade and early clinical outcomes among people living with HIV before and during the COVID-19 pandemic - a prospective multisite cohort study from Ghana.
    Int J Infect Dis. 2023 Jan 9:S1201-9712(22)00683.
    PubMed     Abstract available


  330. JANG YR, Oh YJ, Kim JY
    Regdanvimab for patients with mild-to-moderate COVID-19: a retrospective cohort study and subgroup analysis of patients with the Delta variant.
    Int J Infect Dis. 2023 Jan 6:S1201-9712(22)00674.
    PubMed     Abstract available


  331. NGUIPDOP-DJOMO P, Oswald WE, Halliday KE, Cook S, et al
    Risk factors for SARS-CoV-2 infection in primary and secondary school students and staff in England in the 2020/2021 school year: a longitudinal study.
    Int J Infect Dis. 2023 Jan 5:S1201-9712(22)00673.
    PubMed     Abstract available


  332. IKEDA M, Okugawa S, Kashiwabara K, Moritoyo T, et al
    Multicenter, Single-Blind, Randomized Controlled Study of the Efficacy and Safety of Favipiravir and Nafamostat Mesilate in Patients with COVID-19 Pneumonia.
    Int J Infect Dis. 2023 Jan 3:S1201-9712(22)00684.
    PubMed     Abstract available


  333. BONACINA F, Boelle PY, Colizza V, Lopez O, et al
    Global patterns and drivers of influenza decline during the COVID-19 pandemic.
    Int J Infect Dis. 2023 Jan 3:S1201-9712(22)00682.
    PubMed     Abstract available


  334. WEE LE, Tan JY, Oon LLE, Pena AMT, et al
    Relapsing COVID-19 infection as a manifestation of Good's syndrome: a case report and literature review.
    Int J Infect Dis. 2023 Jan 3:S1201-9712(22)00681.
    PubMed     Abstract available


    December 2022
  335. JOO KIM W, Roberts CC, Young Song J, Yoon JG, et al
    Safety and immunogenicity of the bi-cistronic GLS-5310 COVID-19 DNA vaccine delivered with the GeneDerm suction device.
    Int J Infect Dis. 2022 Dec 30:S1201-9712(22)00678.
    PubMed     Abstract available


  336. JASSAT W, Mudara C, Vika C, Welch R, et al
    A cohort study of Post COVID-19 Condition across the Beta, Delta and Omicron waves in South Africa: 6-month follow up of hospitalised and non-hospitalised participants.
    Int J Infect Dis. 2022 Dec 29:S1201-9712(22)00676.
    PubMed     Abstract available


  337. KOHMER N, Stein S, Schenk B, Grikscheit K, et al
    Heterologous prime-boost immunisation with ChAdOx1-S and BNT162b2: reactogenicity and immunogenicity in a prospective cohort study.
    Int J Infect Dis. 2022 Dec 29:S1201-9712(22)00672.
    PubMed     Abstract available


  338. MARKL B, Dintner S, Schaller T, Sipos E, et al
    Fatal cases after Omicron BA.1 and BA.2 infection: results of an autopsy study.
    Int J Infect Dis. 2022 Dec 27:S1201-9712(22)00669.
    PubMed     Abstract available


  339. YANG SL, Ripen AM, Ven Lee J, Koh K, et al
    Time from last immunity event against infection during Omicron dominant period in Malaysia.
    Int J Infect Dis. 2022 Dec 26:S1201-9712(22)00667.
    PubMed     Abstract available


  340. KAIZER AM, Shapiro NI, Wild J, Brown SM, et al
    Lopinavir/ritonavir for Treatment of Non-Hospitalized Patients with COVID-19: A Randomized Clinical Trial.
    Int J Infect Dis. 2022 Dec 26:S1201-9712(22)00665.
    PubMed     Abstract available


  341. HEIDARZADEH A, Moridani MA, Khoshmanesh S, Kazemi S, et al
    Effectiveness of COVID-19 vaccines on hospitalization and death in Guilan, Iran: a test negative case-control study.
    Int J Infect Dis. 2022 Dec 23:S1201-9712(22)00664.
    PubMed     Abstract available


  342. MOHAMMED NI, Mackenzie G, Ezeani E, Sidibeh M, et al
    Quantifying Excess Mortality during the Covid-19 pandemic in 2020 in The Gambia: A time-series analysis of three Health and Demographic Surveillance Systems.
    Int J Infect Dis. 2022 Dec 22:S1201-9712(22)00654.
    PubMed     Abstract available


  343. WESTERHOF I, de Hoog M, Ieven M, Lammens C, et al
    The impact of variant and vaccination on SARS-CoV-2 symptomatology; three prospective household cohorts.
    Int J Infect Dis. 2022 Dec 22:S1201-9712(22)00656.
    PubMed     Abstract available


  344. WATASE M, Masaki K, Chubachi S, Namkoong H, et al
    Impact of accumulative smoking exposure and chronic obstructive pulmonary disease on COVID-19 outcomes: Report based on findings from the Japan COVID-19 Task Force.
    Int J Infect Dis. 2022 Dec 20:S1201-9712(22)00655.
    PubMed     Abstract available


  345. FANO-SIZGORICH D, Vasquez-Velasquez C, Orellana LR, Ponce-Torres C, et al
    RISK OF DEATH, HOSPITALIZATION AND ICU ADMISSION BY SARS-CoV-2 VARIANTS IN PERU, A RETROSPECTIVE STUDY.
    Int J Infect Dis. 2022 Dec 20:S1201-9712(22)00657.
    PubMed     Abstract available


  346. PLASSE TF, Delgado B, Potts J, Abramson D, et al
    Randomized, placebo-controlled pilot study of upamostat, a host-directed serine protease inhibitor, for outpatient treatment of COVID-19.
    Int J Infect Dis. 2022 Dec 19:S1201-9712(22)00638.
    PubMed     Abstract available


  347. TENE L, Bergroth T, Eisenberg A, Ben David SS, et al
    Risk factors, health outcomes, healthcare services utilization, and direct medical costs of long COVID patient.
    Int J Infect Dis. 2022 Dec 15:S1201-9712(22)00640.
    PubMed     Abstract available


  348. PERETA I, Moracho A, Lopez N, Ibanez B, et al
    Hospital at Home treatment with Remdesivir for patients with COVID-19: Real life experience.
    Int J Infect Dis. 2022 Dec 12:S1201-9712(22)00648.
    PubMed     Abstract available


  349. NGALAMIKA O, Lidenge SJ, Mukasine MC, Kawimbe M, et al
    SARS-CoV-2 Specific T-cell and Humoral Immunity in HIV-infected and -uninfected Individuals in an African Population: A Prospective Cohort Study.
    Int J Infect Dis. 2022 Dec 11:S1201-9712(22)00646.
    PubMed     Abstract available


  350. TORRES C, Garcia J, Mesle F, Barbieri M, et al
    Identifying age- and sex-specific COVID-19 mortality trends over time in six countries.
    Int J Infect Dis. 2022 Dec 9:S1201-9712(22)00641.
    PubMed     Abstract available


  351. NGIAM JN, Chhabra S, Goh W, Sim MY, et al
    Continued demographic shifts in hospitalised COVID-19 patients from migrant workers to a vulnerable and more elderly local population at risk of severe disease.
    Int J Infect Dis. 2022 Dec 9:S1201-9712(22)00643.
    PubMed     Abstract available


  352. GUO Y, Wang H, Xiao M, Guan X, et al
    Long-term outcomes of COVID-19 convalescents: An 18.5-month longitudinal study in Wuhan.
    Int J Infect Dis. 2022 Dec 9:S1201-9712(22)00642.
    PubMed     Abstract available


  353. GARCIA HAV, Adu PA, Harrigan S, Wilton J, et al
    Risk factors for COVID-19 hospitalization following COVID-19 Vaccination: a population-based cohort study in Canada.
    Int J Infect Dis. 2022 Dec 8:S1201-9712(22)00639.
    PubMed     Abstract available


  354. LUO Y, Lv H, Zhao S, Sun Y, et al
    Age-related seroprevalence trajectories of seasonal coronaviruses in children including neonates in Guangzhou, China.
    Int J Infect Dis. 2022 Dec 5:S1201-9712(22)00636.
    PubMed     Abstract available


  355. NYAGWANGE J, Kutima B, Mwai K, Karanja HK, et al
    Serum IgG and mucosal IgA antibodies from pre-pandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro.
    Int J Infect Dis. 2022 Dec 4:S1201-9712(22)00633.
    PubMed     Abstract available


  356. VUORIO A, Raal F, Kovanen PT
    Drug-drug interaction with oral antivirals for early treatment of COVID-19.
    Int J Infect Dis. 2022 Dec 2:S1201-9712(22)00632.
    PubMed    


  357. LARSEN CS
    Drug-drug interaction with oral antivirals for early treatment of COVID-19 - Authors' reply.
    Int J Infect Dis. 2022 Dec 2:S1201-9712(22)00631.
    PubMed    


    November 2022
  358. FRIMPONG SO, Paintsil E
    Community engagement in Ebola outbreaks in sub-Saharan Africa and implications for COVID-19 control: A scoping review.
    Int J Infect Dis. 2022 Nov 30:S1201-9712(22)00625.
    PubMed     Abstract available


  359. FOWOKAN A, Samji H, Puyat J, Janjua N, et al
    Effectiveness of COVID-19 Vaccines in People Living with HIV in British Columbia and comparisons with a matched HIV-Negative Cohort: A Test Negative Design.
    Int J Infect Dis. 2022 Nov 30:S1201-9712(22)00624.
    PubMed     Abstract available


  360. WU S, Li Y, Mishra S, Bodner K, et al
    Effect of the incremental protection of previous infection against Omicron infection among individuals with a hybrid of infection- and vaccine-induced immunity: a population-based cohort study in Canada.
    Int J Infect Dis. 2022 Nov 28:S1201-9712(22)00620.
    PubMed     Abstract available


  361. CHUNG HY, Jian MJ, Chang CK, Chen CS, et al
    The application of a novel 5-in-1 multiplex RT-PCR assay for rapid detection of SARS-CoV-2 and differentiation between variants of concern.
    Int J Infect Dis. 2022 Nov 28:S1201-9712(22)00619.
    PubMed     Abstract available


  362. DAVIES MA, Morden E, Rosseau P, Arendse J, et al
    Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa.
    Int J Infect Dis. 2022 Nov 24:S1201-9712(22)00615.
    PubMed     Abstract available


  363. MIOCH D, Vanbrabant L, Reimerink J, Kuiper S, et al
    SARS-CoV-2 antibodies persist up to 12 months after natural infection in healthy employees working in non-medical contact-intensive professions.
    Int J Infect Dis. 2022 Nov 24:S1201-9712(22)00616.
    PubMed     Abstract available


  364. KANOKUDOM S, Chansaenroj J, Suntronwong N, Assawakosri S, et al
    Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (Covovax(TM)) after homologous and heterologous two-dose regimens.
    Int J Infect Dis. 2022 Nov 22:S1201-9712(22)00614.
    PubMed     Abstract available


  365. BYGDELL M, Leach S, Lundberg L, Gyll D, et al
    A comprehensive characterisation of patients diagnosed with post-COVID-19 condition in Sweden 16 months after the introduction of the ICD-10 diagnosis code (U09.9): a population-based cohort study.
    Int J Infect Dis. 2022 Nov 18:S1201-9712(22)00612.
    PubMed     Abstract available


  366. PUGA-GOMEZ R, Ricardo-Delgado Y, Rojas-Iriarte C, Cespedes-Henriquez L, et al
    Open-label phase I/II clinical trial of SARS-CoV-2 RBD-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with RBD-protein vaccine (FINLAY-FR-1A) in children.
    Int J Infect Dis. 2022 Nov 17:S1201-9712(22)00601.
    PubMed     Abstract available


  367. LANGER-GOULD A, Xu S, Myers LC, Chen A, et al
    Anakinra or high-dose corticosteroids in COVID-19 pneumonia patients who deteriorate on low-dose dexamethasone: An observational study of comparative effectiveness.
    Int J Infect Dis. 2022 Nov 17:S1201-9712(22)00603.
    PubMed     Abstract available


  368. JUTHI RT, Sazed SA, Sarmin M, Haque R, et al
    COVID-19 and Diarrhea: Putative Mechanisms and Management.
    Int J Infect Dis. 2022 Nov 17:S1201-9712(22)00602.
    PubMed     Abstract available


  369. BRUNVOLL SH, Nygaard AB, Fagerland MW, Holland P, et al
    Post-acute symptoms 3-15 months after COVID-19 among unvaccinated and vaccinated individuals with a breakthrough infection.
    Int J Infect Dis. 2022 Nov 11. pii: S1201-9712(22)00596.
    PubMed     Abstract available


  370. INTAWONG K, Chariyalertsak S, Chalom K, Wonghirundecha T, et al
    Heterologous third and fourth dose vaccines reduce severity and mortality in COVID-19 patients during the periods of delta and omicron predominance in Thailand.
    Int J Infect Dis. 2022 Nov 10. pii: S1201-9712(22)00593.
    PubMed     Abstract available


  371. LV Y, Yu G, Zhang X, Gu J, et al
    Comparative analysis of elderly hospitalized patients with coronavirus disease 2019 or influenza A H1N1 virus infections.
    Int J Infect Dis. 2022 Nov 9. pii: S1201-9712(22)00590.
    PubMed     Abstract available


  372. DECENTI EC, Salvatore MA, Mancon A, Portella G, et al
    A large series of molecular and serological specimens to evaluate mother-to-child SARS-CoV-2 transmission: a prospective study from the Italian Obstetric Surveillance System.
    Int J Infect Dis. 2022 Nov 8. pii: S1201-9712(22)00584.
    PubMed     Abstract available


  373. KITAGAWA H, Nomura T, Kaiki Y, Kakimoto M, et al
    Viable SARS-CoV-2 detected in the air of hospital rooms of COVID-19 patients with early infection.
    Int J Infect Dis. 2022 Nov 7. pii: S1201-9712(22)00589.
    PubMed     Abstract available


  374. SALDIVAR-ESPINOZA B, Macip G, Pujadas G, Garcia-Vallve S, et al
    Could nucleocapsid be a next-generation COVID-19 vaccine candidate?
    Int J Infect Dis. 2022 Nov 5. pii: S1201-9712(22)00586.
    PubMed    


  375. S S, J LR, N W, P M, et al
    High prevalence of SARS-CoV-2 antibodies in pregnant women, after the second wave of infections in the inner city of Johannesburg, Gauteng Province, South Africa.
    Int J Infect Dis. 2022 Nov 5. pii: S1201-9712(22)00575.
    PubMed     Abstract available


  376. ORONS B, Larson C, Caroen S, Reid TR, et al
    Could nucleocapsid be a next-generation COVID-19 vaccine candidate - author's reply.
    Int J Infect Dis. 2022 Nov 5. pii: S1201-9712(22)00587.
    PubMed    


  377. MUHAMMAD AZAMI NA, Perera D, Thayan R, Bakar SA, et al
    SARS-CoV-2 genomic surveillance in Malaysia: Displacement of B.1.617.2 with AY lineages as dominant Delta variants and the introduction of Omicron during the fourth epidemic wave.
    Int J Infect Dis. 2022 Nov 3. pii: S1201-9712(22)00582.
    PubMed     Abstract available


  378. ALVAREZ-DIAZ DA, Ruiz-Moreno HA, Zapata-Bedoya S, Franco-Munoz C, et al
    Clinical outcomes associated with Mu variant infection during the third epidemic peak of COVID-19 in Colombia.
    Int J Infect Dis. 2022 Nov 1. pii: S1201-9712(22)00566.
    PubMed     Abstract available


    October 2022
  379. LAKATOS B, Szabo BG, Bobek I, Kiss-Dala N, et al
    Baricitinib versus tocilizumab treatment for hospitalized adult patients with severe COVID-19 and associated cytokine storm: A prospective, investigational, real-world study.
    Int J Infect Dis. 2022 Oct 31. pii: S1201-9712(22)00577.
    PubMed     Abstract available


  380. FARRONI C, Aiello A, Picchianti-Diamanti A, Lagana B, et al
    Booster dose of SARS-CoV-2 mRNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: A prospective multicenter longitudinal study.
    Int J Infect Dis. 2022 Oct 31. pii: S1201-9712(22)00576.
    PubMed     Abstract available


  381. MATONO T, Izumiya H, Koga H, Kaku M, et al
    Epidemiologic and genomic investigations of an unusual increase in Salmonella enterica serovar Paratyphi A infection among travelers returning from Myanmar in 2015.
    Int J Infect Dis. 2022;125:170-176.
    PubMed     Abstract available


  382. LANGER-GOULD A, Xu S, Myers LC, Chen A, et al
    High-dose corticosteroids in patients hospitalized for COVID-19 pneumonia: an observational study of comparative effectiveness.
    Int J Infect Dis. 2022;125:184-191.
    PubMed     Abstract available


  383. XIN H, Wang Z, Feng S, Sun Z, et al
    Transmission dynamics of SARS-CoV-2 Omicron variant infections in Hangzhou, Zhejiang, China, January-February 2022.
    Int J Infect Dis. 2022;126:132-135.
    PubMed     Abstract available


  384. VISSER MPJ, Walk J, Vermeer C, Bilkova S, et al
    Enhanced vitamin K expenditure as a major contributor to vitamin K deficiency in COVID-19.
    Int J Infect Dis. 2022;125:275-277.
    PubMed     Abstract available


  385. CHEN CS, Chang CN, Chen SJ, Hu CF, et al
    Workup of cerebral involvement in patients with COVID-19 - authors' reply.
    Int J Infect Dis. 2022 Oct 26. pii: S1201-9712(22)00563.
    PubMed    


  386. SCORZA CA, Finsterer J, Scorza FA, Almeida AG, et al
    Workup of cerebral involvement in COVID-19 requires at least cerebral imaging, EEG, and cerebrospinal fluid studies.
    Int J Infect Dis. 2022 Oct 20. pii: S1201-9712(22)00564.
    PubMed    


  387. WANG X, Wen D, He Q, Yang J, et al
    Effect of Corticosteroids in Patients with COVID-19: A Bayesian Network Meta-analysis: Corticosteroids in COVID-19.
    Int J Infect Dis. 2022 Oct 19. pii: S1201-9712(22)00557.
    PubMed     Abstract available


  388. SESSA R, Masciullo L, Filardo S, Pietro MD, et al
    SARS-CoV-2 vertical transmission in a twin-pregnant woman: a case report.
    Int J Infect Dis. 2022 Oct 19. pii: S1201-9712(22)00558.
    PubMed     Abstract available


  389. BLACKMORE C, Czachorowski M, Farrington E, O'Moore E, et al
    Testing for COVID-19 during an outbreak within a large UK prison: an evaluation of mass testing to inform outbreak control.
    Int J Infect Dis. 2022 Oct 17. pii: S1201-9712(22)00556.
    PubMed     Abstract available


  390. DAHL VN, Molhave M, Floe A, van Ingen PJ, et al
    Global trends of pulmonary infections with nontuberculous mycobacteria: a systematic review.
    Int J Infect Dis. 2022 Oct 13. pii: S1201-9712(22)00551.
    PubMed     Abstract available


  391. YIN J, Chen Y, Li Y, Wang C, et al
    Immunogenicity and efficacy of COVID-19 vaccines in people living with HIV: a systematic review and meta-analysis.
    Int J Infect Dis. 2022 Oct 11. pii: S1201-9712(22)00542.
    PubMed     Abstract available


  392. WANG X, Xu H, Chu P, Zeng Y, et al
    Effects of COVID-19-targeted NPIs on children's respiratory admissions in China: a national multicenter time series study.
    Int J Infect Dis. 2022 Oct 11. pii: S1201-9712(22)00546.
    PubMed     Abstract available


  393. AGGARWAL NR, Beaty LE, Bennett TD, Carlson NE, et al
    Change in Effectiveness of Sotrovimab for Preventing Hospitalization and Mortality for At-risk COVID-19 Outpatients During an Omicron BA.1 and BA.1.1-Predominant Phase.
    Int J Infect Dis. 2022 Oct 10. pii: S1201-9712(22)00540.
    PubMed     Abstract available


  394. MIMURA W, Ishiguro C, Maeda M, Murata F, et al
    Effectiveness of mRNA vaccines against SARS-CoV-2 infections during the periods of Delta and Omicron variant predominance in Japan: The VENUS Study.
    Int J Infect Dis. 2022 Oct 8. pii: S1201-9712(22)00539.
    PubMed     Abstract available


  395. DE FREITAS AVC, Magalhaes AM, Carricondo PC, Avakian Shinzato A, et al
    Face masks can reduce the frequency of face touching: an observational crossover study.
    Int J Infect Dis. 2022;123:54-57.
    PubMed     Abstract available


    September 2022
  396. DAITCH V, Yelin D, Awwad M, Guaraldi G, et al
    Characteristics of long COVID among older adults: a cross-sectional study.
    Int J Infect Dis. 2022 Sep 30. pii: S1201-9712(22)00535.
    PubMed     Abstract available


  397. MUADCHIMKAEW M, Siripongboonsitti T, Wongpatcharawarakul S, Boonsankaew C, et al
    Effect of Inactivated SARS-CoV-2 Vaccines and ChAdOx1 nCoV-19 Vaccination to Prevent COVID-19 in Thai Households (VacPrevent trial).
    Int J Infect Dis. 2022 Sep 27. pii: S1201-9712(22)00531.
    PubMed     Abstract available


  398. ALHINAI Z, Park S, Choe YJ, Michelow IC, et al
    A global epidemiological analysis of COVID-19 vaccine types and clinical outcomes.
    Int J Infect Dis. 2022 Sep 22. pii: S1201-9712(22)00514.
    PubMed     Abstract available


  399. CHOBER D, Czajkowski Z, Aksak-Was B, Dalewska-Kucharczyk K, et al
    Improved survival in ICU in severe COVID-19 associated with amantadine use - retrospective study.
    Int J Infect Dis. 2022 Sep 21. pii: S1201-9712(22)00525.
    PubMed     Abstract available


  400. ZAQOUT A, Almaslamani MA, Chemaitelly H, Hashim SA, et al
    Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar.
    Int J Infect Dis. 2022;124:96-103.
    PubMed     Abstract available


  401. TAMURA D, Yamagishi H, Morisawa Y, Mato T, et al
    Diagnostic accuracy of a novel severe acute respiratory syndrome coronavirus 2 rapid antigen test and usefulness of specimens collected from the anterior nasal cavity.
    Int J Infect Dis. 2022 Sep 16. pii: S1201-9712(22)00517.
    PubMed     Abstract available


  402. FENIZIA C, Vanetti C, Rana F, Cappelletti G, et al
    SARS-CoV-2 vertical transmission during the first trimester of pregnancy in asymptomatic women.
    Int J Infect Dis. 2022 Sep 16. pii: S1201-9712(22)00520.
    PubMed     Abstract available


  403. KUBO M, Kubo K, Kobayashi KI, Komiya N, et al
    Non-severe COVID-19 complicated by cytotoxic lesions of the corpus callosum (mild encephalitis/encephalopathy with a reversible splenial lesion): a case report and literature review.
    Int J Infect Dis. 2022 Sep 16. pii: S1201-9712(22)00508.
    PubMed     Abstract available


  404. ANDO M, Satonaga Y, Takaki R, Yabe M, et al
    Acute asthma exacerbation due to SARS-CoV-2 vaccine (Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine [Comirnaty(R)]).
    Int J Infect Dis. 2022 Sep 16. pii: S1201-9712(22)00518.
    PubMed     Abstract available


  405. VICENTINI C, Bordino V, Cornio AR, Meddis D, et al
    Seroprevalence of infection-induced SARS-CoV-2 antibodies among healthcare users of Northern Italy - results from two serosurveys (October-November 2019 - September-October 2021).
    Int J Infect Dis. 2022 Sep 15. pii: S1201-9712(22)00513.
    PubMed     Abstract available


  406. ROTUNDO S, Vecchio E, Abatino A, Giordano C, et al
    Spike-specific T-cell responses in COVID-19 patients successfully treated with neutralizing monoclonal antibodies against SARS-CoV-2.
    Int J Infect Dis. 2022 Sep 15. pii: S1201-9712(22)00515.
    PubMed     Abstract available


  407. KIM AY, Woo W, Yon DK, Lee SW, et al
    Corrigendum to 'Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A Systematic Review and Meta-Analysis' International Journal of Infectious Diseases, Volume 119, June 2022, Page 130-139.
    Int J Infect Dis. 2022;123:166.
    PubMed    


  408. D'ABRAMO A, Vita S, Colavita F, Cimini E, et al
    The first case of meningitis associated to SARS-Coronavirus-2 BA.2 variant infection with persistent viremia.
    Int J Infect Dis. 2022 Sep 12. pii: S1201-9712(22)00510.
    PubMed     Abstract available


  409. ANTONAZZO IC, Fornari C, Rozza D, Conti S, et al
    Azithromycin use and outcomes in COVID-19 patients: an observational real-world study.
    Int J Infect Dis. 2022 Sep 8. pii: S1201-9712(22)00504.
    PubMed     Abstract available


  410. GIUSEPPE S, Guarini R, Vaia F, Maggi F, et al
    Monitoring of SARS-CoV-2 circulation using saliva testing in school children, Rome, Italy.
    Int J Infect Dis. 2022 Sep 8. pii: S1201-9712(22)00502.
    PubMed     Abstract available


  411. ZAYET S, Vuillemenot JB, Josset L, Gendrin V, et al
    Simultaneous co-infection with Omicron (B.1.1.529) and Delta (21A/478K.V1) SARS-CoV-2 variants confirmed by whole genome sequencing.
    Int J Infect Dis. 2022 Sep 7. pii: S1201-9712(22)00501.
    PubMed     Abstract available


  412. CHEN CS, Chang CN, Hu CF, Jian MJ, et al
    Critical pediatric neurological illness associated with COVID-19 (Omicron BA.2.3.7 variant) infection in Taiwan: Immunological assessment and viral genome analysis in tertiary medical center.
    Int J Infect Dis. 2022 Sep 7. pii: S1201-9712(22)00500.
    PubMed     Abstract available


  413. ABROI A, Talas UG, Pauskar M, Shablinskaja A, et al
    SARS-CoV-2 dual infection of Delta and Omicron variants in an immunocompetent host - a case report.
    Int J Infect Dis. 2022 Sep 5. pii: S1201-9712(22)00497.
    PubMed     Abstract available


  414. LI YE, Wang S, Reiter RJ, Ren J, et al
    Clinical Cardiovascular Emergencies and the Cellular Basis of COVID-19 Vaccination: from a Dream to Reality?
    Int J Infect Dis. 2022 Sep 5. pii: S1201-9712(22)00498.
    PubMed     Abstract available


  415. LEE SS, Viboud C, Petersen E
    Understanding the rebound of influenza in the post COVID-19 pandemic period holds important clues for epidemiology and control.
    Int J Infect Dis. 2022;122:1002-1004.
    PubMed    


    August 2022
  416. WAITS A, Chen JY, Cheng WH, Yeh JI, et al
    Safety and Immunogenicity of MVC-COV1901 Vaccine in Older Adults: Phase 2 Randomized Dose-Comparison Trial.
    Int J Infect Dis. 2022 Aug 29. pii: S1201-9712(22)00491.
    PubMed     Abstract available


  417. BRUNNER WM, Freilich D, Victory J, Krupa N, et al
    Comparison of Antibody Response Durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 Vaccines in Healthcare Workers.
    Int J Infect Dis. 2022 Aug 28. pii: S1201-9712(22)00492.
    PubMed     Abstract available


  418. ASSERI AA, Assiri M, Alshehri MA, Asseri M, et al
    Acute Encephalopathy in a 6-Year-Old Child with Concurrent Coronavirus Disease-2019 Infection: A Case Report from Saudi Arabia.
    Int J Infect Dis. 2022 Aug 20. pii: S1201-9712(22)00483.
    PubMed     Abstract available


  419. SAINZ-GARCIA A, Toledano P, Muro-Fraguas I, Alvarez-Erviti L, et al
    Mask Disinfection using Atmospheric Pressure Cold Plasma.
    Int J Infect Dis. 2022 Aug 19. pii: S1201-9712(22)00482.
    PubMed     Abstract available


  420. OEHLER RL, Vega VR
    Global Vaccine Inequality Threatens to Unleash the Next COVID-19 Variant.
    Int J Infect Dis. 2022 Aug 18. pii: S1201-9712(22)00480.
    PubMed     Abstract available


  421. GHAFFARZADEGAN N
    Effect of mandating vaccination on COVID-19 cases in colleges and universities.
    Int J Infect Dis. 2022 Aug 17. pii: S1201-9712(22)00477.
    PubMed     Abstract available


  422. VIEL S, Markowicz S, Ait-Medjber L, Ouissa R, et al
    Dedicated team to ambulatory care for patients with COVID-19 requiring oxygen: low rate of hospital readmission.
    Int J Infect Dis. 2022 Aug 17. pii: S1201-9712(22)00452.
    PubMed     Abstract available


  423. YU T, Liu F, Yin H, Yi N, et al
    Comment to the article by Pedro Brotons: Validation and implementation of a direct RT-qPCR method for rapid screening of SARS-CoV-2 infection by using non-invasive saliva samples, IJID 110 (2021) 363-370.
    Int J Infect Dis. 2022 Aug 17. pii: S1201-9712(22)00478.
    PubMed    


  424. SANCHEZ-CONDE M, Vizcarra P, Perez-Garcia JM, Gion M, et al
    Pembrolizumab in combination with tocilizumab in high-risk hospitalized COVID-19 patients (COPERNICO): A randomized proof-of-concept phase II study.
    Int J Infect Dis. 2022 Aug 17. pii: S1201-9712(22)00475.
    PubMed     Abstract available


  425. NAVARATNAM AMD, Shrotri M, Nguyen V, Braithwaite I, et al
    Nucleocapsid and spike antibody responses post virologically confirmed SARS-CoV-2 infection: An observational analysis in the Virus Watch community cohort.
    Int J Infect Dis. 2022 Aug 17. pii: S1201-9712(22)00449.
    PubMed     Abstract available


  426. RAYMENANTS J, Duthoo W, Stakenborg T, Verbruggen B, et al
    Exhaled breath SARS-CoV-2 shedding patterns across variants of concern.
    Int J Infect Dis. 2022 Aug 3. pii: S1201-9712(22)00466.
    PubMed     Abstract available


  427. LIANG Y, Mao X, Kuang M, Zhi J, et al
    IL-6 affects the severity of olfactory disorder: A cross-sectional survey of 148 patients who recovered from Omicron infection using the Sniffin' Sticks test in Tianjin, China.
    Int J Infect Dis. 2022 Aug 2. pii: S1201-9712(22)00468.
    PubMed     Abstract available


  428. ALMADHI M, Alsayyad AS, Conroy R, Atkin S, et al
    EPIDEMIOLOGICAL ASSESSMENT OF SARS-COV-2 REINFECTION.
    Int J Infect Dis. 2022 Aug 2. pii: S1201-9712(22)00470.
    PubMed     Abstract available


    July 2022
  429. DE OLIVEIRA JF, de Avila RE, de Oliveira NR, da Cunha Severino Sampaio N, et al
    Persistent symptoms, quality of life and risk factors in long COVID: a cross-sectional study of hospitalized patients in Brazil.
    Int J Infect Dis. 2022 Jul 28. pii: S1201-9712(22)00458.
    PubMed     Abstract available


  430. SRECKOVIC M, Marjanovic RR, Jovicic BP, Jankovic S, et al
    MULTISYSTEM INFLAMMATORY SYNDROME IN YOUNG ADULT SUCCESSFULLY TREATED WITH PLASMAPHERESIS, IMMUNOGLOBULINS AND CORTICOSTEROIDS: A CASE REPORT.
    Int J Infect Dis. 2022 Jul 28. pii: S1201-9712(22)00454.
    PubMed     Abstract available


  431. LI T, Song R, Wang J, Zhang J, et al
    Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people with gastrointestinal cancer.
    Int J Infect Dis. 2022 Jul 26. pii: S1201-9712(22)00446.
    PubMed     Abstract available


  432. DAHAL S, Mamelund SE, Luo R, Sattenspiel L, et al
    Investigating COVID-19 transmission and mortality differences among Indigenous and non-Indigenous populations in Mexico.
    Int J Infect Dis. 2022 Jul 26. pii: S1201-9712(22)00447.
    PubMed     Abstract available


  433. AIELLO A, Coppola A, Vanini V, Petrone L, et al
    Accuracy of QuantiFERON SARS-CoV-2 RUO assay and characterization of the CD4(+) and CD8(+) T-cell-SARS-CoV-2 response: comparison with a homemade IFN-gamma release assay.
    Int J Infect Dis. 2022 Jul 22. pii: S1201-9712(22)00444.
    PubMed     Abstract available


  434. DORIA G, Clemente C, Coelho E, Colaco J, et al
    An isothermal lab-on-phone test for easy molecular diagnostic of SARS-CoV-2 near patient and in less than 1 hour.
    Int J Infect Dis. 2022 Jul 22. pii: S1201-9712(22)00436.
    PubMed     Abstract available


  435. VALLADARES-GARRIDO MJ, Failoc-Rojas VE, Soto-Becerra P, Zena-Nanez S, et al
    Clinical-epidemiological variation in patients treated in the first and second wave of COVID-19 in Lambayeque, Peru: A cluster analysis.
    Int J Infect Dis. 2022 Jul 21. pii: S1201-9712(22)00442.
    PubMed     Abstract available


  436. VILLAFUERTE DB, Lavrynenko O, Qazi R, Passeri MF, et al
    Chronic Active Epstein-Barr Exacerbated by COVID-19 Co-Infection.
    Int J Infect Dis. 2022 Jul 21. pii: S1201-9712(22)00439.
    PubMed     Abstract available


  437. AKHMETZHANOV AR, Ponce L, Thompson RN
    Emergence potential of Monkeypox in the Western Pacific Region, July 2022.
    Int J Infect Dis. 2022 Jul 21. pii: S1201-9712(22)00441.
    PubMed     Abstract available


  438. LU J, Zhu J, Zhu J, Duong TQ, et al
    LSTM machine learning of longitudinal clinical data accurately predicts acute kidney injury onset in COVID-19: a two-center study.
    Int J Infect Dis. 2022 Jul 21. pii: S1201-9712(22)00429.
    PubMed     Abstract available


  439. ASSAWAKOSRI S, Kanokudom S, Chansaenroj J, Suntronwong N, et al
    Persistence of immunity against Omicron BA.1 and BA.2 following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222 vaccination.
    Int J Infect Dis. 2022 Jul 18. pii: S1201-9712(22)00433.
    PubMed     Abstract available


  440. BAIRD D, Muir A, Logan L, MacLennan M, et al
    Validation of the NeuMoDx SARS-CoV-2 Assay with COPAN eNAT(R) and E&O Viral PCR Sample Solution (VPSS) collection media types in comparison with other validated SARS-CoV-2 RNA assays.
    Int J Infect Dis. 2022 Jul 15. pii: S1201-9712(22)00418.
    PubMed     Abstract available


  441. BHATNAGAR T, Chaudhuri S, Ponnaiah M, Yadav PD, et al
    Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: A multi-centric hospital-based case-control study.
    Int J Infect Dis. 2022 Jul 14. pii: S1201-9712(22)00427.
    PubMed     Abstract available


  442. YIN Q, Li Y, Pan H, Hui T, et al
    Atypical pneumonia caused by Chlamydia Psittaci during the COVID-19 pandemic.
    Int J Infect Dis. 2022 Jul 13. pii: S1201-9712(22)00422.
    PubMed     Abstract available


  443. VOOR IN 'T HOLT AF, Haanappel CP, Rahamat-Langendoen J, Molenkamp R, et al
    Admissions to a large tertiary care hospital and Omicron BA.1 and BA.2 SARS-CoV-2 PCR positivity: primary, contributing, or incidental COVID-19.
    Int J Infect Dis. 2022 Jul 13. pii: S1201-9712(22)00424.
    PubMed     Abstract available


  444. MAAMARI KA, Busaidi IA, Kindi MA, Zadjali F, et al
    Short and long-term immune changes in different severity groups of COVID-19 disease.
    Int J Infect Dis. 2022 Jul 12. pii: S1201-9712(22)00421.
    PubMed     Abstract available


  445. ALOTAIBY M, Krissaane I, Seraihi AA, Alshenaifi J, et al
    SARS-CoV-2 Reinfection Rate and Outcomes in Saudi Arabia: A National Retrospective Study.
    Int J Infect Dis. 2022 Jul 12. pii: S1201-9712(22)00420.
    PubMed     Abstract available


  446. JUANOLA-FALGARONA M, Penarrubia L, Jimenez-Guzman S, Porco R, et al
    Ct values as a diagnostic tool for monitoring SARS-CoV-2 viral load using the QIAstat-Dx(R) Respiratory SARS-CoV-2 Panel.
    Int J Infect Dis. 2022 Jul 12. pii: S1201-9712(22)00419.
    PubMed     Abstract available


  447. TOCZYLOWSKI K, Lasecka-Zadrozna J, Palyga-Bysiecka I, Ludwikowska KM, et al
    Use of broad-spectrum antibiotics in children diagnosed with multisystem inflammatory syndrome temporarily associated with SARS-CoV-2 infection in Poland: the MOIS-CoR study.
    Int J Infect Dis. 2022 Jul 10. pii: S1201-9712(22)00416.
    PubMed     Abstract available


  448. DASTENAE ZH, Bahadori A, Dehghani M, Asadi-Samani M, et al
    Comparison of the effect of intravenous dexamethasone and methylprednisolone on the treatment of hospitalized patients with COVID-19: A randomized clinical trial.
    Int J Infect Dis. 2022 Jul 8. pii: S1201-9712(22)00413.
    PubMed     Abstract available


  449. PETERSEN MS, Kongsstovu SI, Eliasen EH, Larsen S, et al
    Clinical characteristics of the Omicron variant - results from a Nationwide Symptoms Survey in the Faroe Islands.
    Int J Infect Dis. 2022 Jul 7. pii: S1201-9712(22)00405.
    PubMed     Abstract available


  450. NATH H, Mallick A, Roy S, Kayal T, et al
    COVID-19 serum can be cross-reactive and neutralizing against Dengue virus (DV) as observed by DV neutralization test.
    Int J Infect Dis. 2022 Jul 7. pii: S1201-9712(22)00408.
    PubMed     Abstract available


  451. BIBER A, Harmelin G, Lev D, Ram L, et al
    The effect of ivermectin on the viral load and culture viability in early treatment of non-hospitalized patients with mild COVID-19 - A double-blind, randomized placebo-controlled trial.
    Int J Infect Dis. 2022 Jul 7. pii: S1201-9712(22)00399.
    PubMed     Abstract available


  452. FUKUSHIMA T, Chubachi S, Namkoong H, Otake S, et al
    U-shaped association between abnormal serum uric acid levels and COVID-19 severity: Reports from the Japan COVID-19 Task Force.
    Int J Infect Dis. 2022 Jul 7. pii: S1201-9712(22)00409.
    PubMed     Abstract available


  453. MURUGESAN M, Venkatesan P, Kumar S, Thangavelu P, et al
    Epidemiological investigation of the COVID-19 outbreak in Vellore district in South India using Geographic Information Surveillance (GIS).
    Int J Infect Dis. 2022 Jul 7. pii: S1201-9712(22)00402.
    PubMed     Abstract available


  454. RICCIARDI A, Zelini P, Cassaniti I, Avanzini MA, et al
    Serum and breastmilk SARS-CoV-2 specific antibodies following BNT162b2 vaccine: Prolonged protection from SARS-CoV-2 in newborns and older children.
    Int J Infect Dis. 2022 Jul 5. pii: S1201-9712(22)00392.
    PubMed     Abstract available


  455. TOBBACK E, Degroote S, Buysse S, Delesie L, et al
    Efficacy and safety of camostat mesylate in early Covid-19 disease in an ambulatory setting: A randomized placebo-controlled phase II trial.
    Int J Infect Dis. 2022 Jul 5. pii: S1201-9712(22)00388.
    PubMed     Abstract available


  456. MALINOWSKA J, Malecka-Gieldowska M, Bankowska D, Borecka K, et al
    Hypermagnesemia and hyperphosphatemia are highly prevalent in COVID-19 patients and increase the risk of death.
    Int J Infect Dis. 2022 Jul 5. pii: S1201-9712(22)00394.
    PubMed     Abstract available


  457. SALEH T, Kerin T, Fuller T, Paiola S, et al
    Clinical and epidemiological characteristics of SARS-CoV-2 Infection in Los Angeles County youth during the first year of the pandemic.
    Int J Infect Dis. 2022 Jul 5. pii: S1201-9712(22)00374.
    PubMed     Abstract available


  458. LARSEN CS
    Assessing the proportion of the Danish population at risk of clinically significant drug-drug interactions with new oral antivirals for early treatment of COVID-19.
    Int J Infect Dis. 2022 Jul 5. pii: S1201-9712(22)00391.
    PubMed     Abstract available


  459. DESWAL V, Phogat R, Sharma P, Kataria S, et al
    Is single dose of ChAdOx1 nCoV-19 vaccine (AZD1222) enough for persons with prior SARS-CoV-2 infection or baseline seropositive status?
    Int J Infect Dis. 2022 Jul 3. pii: S1201-9712(22)00384.
    PubMed    


  460. DING L, Chen Y, Su N, Xu X, et al
    Comparison of acute respiratory distress syndrome in patients with COVID-19 and influenza A (H7N9) virus infection.
    Int J Infect Dis. 2022 Jul 3. pii: S1201-9712(22)00387.
    PubMed     Abstract available


  461. KOH K, Tang KC, Axhausen K, Loo BP, et al
    A metropolitan-scale, three-dimensional agent-based model to assess the effectiveness of the COVID-19 Omicron wave interventions in a hyperdense city: a case study of Hong Kong.
    Int J Infect Dis. 2022 Jul 3. pii: S1201-9712(22)00376.
    PubMed     Abstract available


  462. XIONG L, Li Q, Cao X, Xiong H, et al
    Recovery of functional fitness, lung function and immune function in health care workers with non-severe and severe COVID-19 at 13 months after discharge from the hospital: a prospective cohort study.
    Int J Infect Dis. 2022 Jul 3. pii: S1201-9712(22)00386.
    PubMed     Abstract available


  463. CHEN NY, Liu ZH, Kao SW, Lin HS, et al
    Changes in Interferon-Gamma Release Assay Readout after COVID-19 Vaccination: A Prospective Cohort Study.
    Int J Infect Dis. 2022 Jul 1. pii: S1201-9712(22)00382.
    PubMed     Abstract available


  464. ORONSKY B, Larson C, Caroen S, Hedjran F, et al
    Nucleocapsid as a Next Generation COVID-19 Vaccine Candidate.
    Int J Infect Dis. 2022 Jul 1. pii: S1201-9712(22)00379.
    PubMed     Abstract available


  465. ISA F, Forleo-Neto E, Meyer J, Zheng W, et al
    Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19.
    Int J Infect Dis. 2022 Jul 1. pii: S1201-9712(22)00380.
    PubMed     Abstract available


    June 2022
  466. FARIDL M, Mellyani K, Khoirunnisa K, Septiani P, et al
    RNA-seq analysis of nasopharyngeal swabs from asymptomatic and mildly symptomatic COVID-19 patients.
    Int J Infect Dis. 2022 Jun 24. pii: S1201-9712(22)00368.
    PubMed     Abstract available


  467. DOS SANTOS PG, Vieira HCVS, Wietholter V, Gallina JP, et al
    When to test for COVID-19 using RT-PCR: a systematic review.
    Int J Infect Dis. 2022 Jun 24. pii: S1201-9712(22)00370.
    PubMed     Abstract available


  468. SBERNA G, Fabeni L, Berno G, Carletti F, et al
    Rapid and qualitative identification of SARS-CoV-2 mutations associated with Variants Of Concern (VOC) using a multiplex RT-PCR assay coupled with melting analysis.
    Int J Infect Dis. 2022 Jun 24. pii: S1201-9712(22)00367.
    PubMed     Abstract available


  469. HIROTSU Y, Maejima M, Shibusawa M, Natori Y, et al
    Classification of Omicron BA.1, BA.1.1 and BA.2 sublineages by TaqMan assay consistent with whole genome analysis data.
    Int J Infect Dis. 2022 Jun 24. pii: S1201-9712(22)00373.
    PubMed     Abstract available


  470. FINSTERER J, Scorza FA
    Rule out appropriately all differentials before attributing severe rhabdomyolysis to SARS-CoV-2 vaccination: COVID-19 associated abdominal epilepsy.
    Int J Infect Dis. 2022 Jun 24. pii: S1201-9712(22)00372.
    PubMed    


  471. KAMURA Y, Matsue K
    Severe rhabdomyolysis and SARS-CoV-2 vaccination: A reply to the letter by Dr Josef Finsterer.
    Int J Infect Dis. 2022 Jun 24. pii: S1201-9712(22)00366.
    PubMed    


  472. PETERSEN MS, Kristiansen MF, Hanusson KD, Foldbo BM, et al
    Prevalence of long COVID in a national cohort: longitudinal measures from disease onset until 8 months follow up.
    Int J Infect Dis. 2022 Jun 23. pii: S1201-9712(22)00364.
    PubMed     Abstract available


  473. RUTER J, Pallerla SR, Meyer CG, Casadei N, et al
    Host genetic loci LZTFL1 and CCL2 associated with SARS-CoV-2 infection and severity of COVID-19.
    Int J Infect Dis. 2022 Jun 23. pii: S1201-9712(22)00365.
    PubMed     Abstract available


  474. KSHATRI JS, Giri S, Bhattacharya D, Palo SK, et al
    Analysis of the COVID-19 testing parameters and progression of the pandemic at the district level- findings from the ICMR- Hundred Million Test (HMT) database during the first wave in India.
    Int J Infect Dis. 2022 Jun 22. pii: S1201-9712(22)00361.
    PubMed     Abstract available


  475. ROVIDA F, Esposito GL, Rissone M, Novelli V, et al
    Characteristics and outcome of vaccinated and non-vaccinated patients hospitalized in a single Italian HUB for COVID-19 during the Delta and Omicron waves in Northern Italy.
    Int J Infect Dis. 2022 Jun 21. pii: S1201-9712(22)00362.
    PubMed     Abstract available


  476. RIZZO R, Bortolotti D, Morandi L, Rizzo S, et al
    Humoral and adaptive immune responses to SARS-CoV-2 vaccine.
    Int J Infect Dis. 2022 Jun 21. pii: S1201-9712(22)00355.
    PubMed     Abstract available


  477. QUARANTA EG, Fusaro A, Giussani E, D'Amico V, et al
    SARS-CoV-2 intra-host evolution during prolonged infection in an immunocompromised patient.
    Int J Infect Dis. 2022 Jun 17. pii: S1201-9712(22)00359.
    PubMed     Abstract available


  478. STAMBOULI N, Driss A, Gargouri F, Bahrini K, et al
    COVID-19 prophylaxis with Doxycycline and Zinc in Health Care Workers: A prospective randomized double-blind clinical trial.
    Int J Infect Dis. 2022 Jun 17. pii: S1201-9712(22)00349.
    PubMed     Abstract available


  479. QIN J, Wang G, Han D
    Benefits of plasma exchange on mortality in patients with COVID-19: a systematic review and meta-analysis.
    Int J Infect Dis. 2022 Jun 13. pii: S1201-9712(22)00348.
    PubMed     Abstract available


  480. KOLLER JE, Villinger K, Lages NC, Absetz P, et al
    Individual and collective protective responses during the early phase of the COVID-19 pandemic in 10 different countries: Results from the EUCLID online-survey.
    Int J Infect Dis. 2022 Jun 13. pii: S1201-9712(22)00347.
    PubMed     Abstract available


  481. CLARO F, Silva D, Bogado JAP, Rangel HR, et al
    Lasting SARS-CoV-2 specific IgG Antibody response in health care workers from Venezuela, 6 months after vaccination with Sputnik V.
    Int J Infect Dis. 2022 Jun 8. pii: S1201-9712(22)00341.
    PubMed     Abstract available


  482. TARNAS MC, Desai AN, Parker DM, Almhawish N, et al
    Syndromic surveillance of respiratory infections during protracted conflict: experiences from northern Syria 2016-2021.
    Int J Infect Dis. 2022 Jun 7. pii: S1201-9712(22)00336.
    PubMed     Abstract available


  483. SASANAMI M, Kayano T, Nishiura H
    Monitoring the COVID-19 immune landscape in Japan.
    Int J Infect Dis. 2022 Jun 7. pii: S1201-9712(22)00338.
    PubMed     Abstract available


  484. MANNATHOKO N, Mospele M, Gross R, Smith RM, et al
    Colonization with Extended-Spectrum Cephalosporin-Resistant Enterobacterales (ESCrE) and Carbapenem-Resistant Enterobacterales (CRE) in Healthcare and Community Settings in Botswana: An Antibiotic Resistance in Communities and Hospitals (ARCH) Study.
    Int J Infect Dis. 2022 Jun 7. pii: S1201-9712(22)00337.
    PubMed     Abstract available


  485. KHONGYOT T, Moriyasu T
    Invasive Pneumococcal Disease diminish during the coronavirus disease 2019 in Japan between 2019 and 2022.
    Int J Infect Dis. 2022 Jun 4. pii: S1201-9712(22)00333.
    PubMed     Abstract available


  486. HERNANDEZ PORTO M, Garcia S, Delgado T, Rodriguez Y, et al
    Humoral response to SARS-COV-2 after vaccination and C in dialyzed patients.
    Int J Infect Dis. 2022 Jun 4. pii: S1201-9712(22)00335.
    PubMed     Abstract available


  487. DIVINO F, Alaimo Di Loro P, Farcomeni A, Jona-Lasinio G, et al
    Decreased severity of the Omicron variant of concern: further evidence from Italy.
    Int J Infect Dis. 2022;119:21-23.
    PubMed    


    May 2022
  488. LAI X, Deng S, Hu L, Chen R, et al
    J-shaped associations and joint effects of fasting glucose with inflammation and cytokines on COVID-19 mortality.
    Int J Infect Dis. 2022 May 31. pii: S1201-9712(22)00324.
    PubMed     Abstract available


  489. BORDI L, Sberna G, Piscioneri CN, Cocchiara RA, et al
    Longitudinal dynamics of SARS-CoV2 anti-Receptor Binding Domain IgG antibodies in a wide population of health care workers after BNT162b2 vaccination.
    Int J Infect Dis. 2022 May 31. pii: S1201-9712(22)00325.
    PubMed     Abstract available


  490. BACHELARD A, Sautereau A, Digumber M, Isernia V, et al
    Risk Factors Associated with Severe/Critical COVID-19 in People Living with HIV-1.
    Int J Infect Dis. 2022 May 29. pii: S1201-9712(22)00320.
    PubMed    


  491. JIN T, Chen X, Nishio M, Zhuang L, et al
    Interventions to prevent surface transmission of an infectious virus based on real human touch behavior: A case study of the norovirus.
    Int J Infect Dis. 2022 May 29. pii: S1201-9712(22)00311.
    PubMed     Abstract available


  492. ALBERTO-ORLANDO S, Calderon JL, Leon-Sosa A, Patino L, et al
    SARS-CoV-2 transmission from infected owner to household dogs and cats is associated to food sharing.
    Int J Infect Dis. 2022 May 25. pii: S1201-9712(22)00313.
    PubMed     Abstract available


  493. TEGETHOFF SA, Danziger G, Kuhn D, Kimmer C, et al
    TRAIL, IP-10, and CRP in predicting the progression of SARS-CoV-2 infection: A prospective, cohort study.
    Int J Infect Dis. 2022 May 25. pii: S1201-9712(22)00315.
    PubMed     Abstract available


  494. ALI M, Bonna AS, Sarkar AS, Islam MA, et al
    SARS-CoV-2 infection is associated with low back pain: Findings from a community based case-control study.
    Int J Infect Dis. 2022 May 25. pii: S1201-9712(22)00312.
    PubMed     Abstract available


  495. WAWINA-BOKALANGA T, Logist AS, Sinnesael R, Van Holm B, et al
    Genomic evidence of co-identification with Omicron and Delta SARS-CoV-2 variants: A report of two cases.
    Int J Infect Dis. 2022 May 20. pii: S1201-9712(22)00304.
    PubMed     Abstract available


  496. KORAYEM GB, Aljuhani O, Altebainawi AF, Shaya AIA, et al
    The Safety and Efficacy of Tocilizumab in Older Adult Critically Ill Patients with Coronavirus Disease 2019 (COVID-19): A Multi-center, Cohort Study.
    Int J Infect Dis. 2022 May 20. pii: S1201-9712(22)00302.
    PubMed     Abstract available


  497. MATTIUZZI C, Lippi G
    Real-world effectiveness of COVID-19 vaccination among children in Italy.
    Int J Infect Dis. 2022 May 19. pii: S1201-9712(22)00309.
    PubMed     Abstract available


  498. NTAGEREKA PB, Oyola SO, Baenyi SP, Rono GK, et al
    Whole-Genome Sequencing of SARS-CoV-2 Reveals Diverse Mutations in Circulating Alpha and Delta Variants during the First, Second and Third Waves of Covid-19 in South Kivu, East of the Democratic Republic of Congo.
    Int J Infect Dis. 2022 May 19. pii: S1201-9712(22)00307.
    PubMed     Abstract available


  499. KUDHAIL K, Thompson J, Mathews V, Morrison B, et al
    Randomised controlled trials in COVID-19 patients: a systematic review and critical appraisal.
    Int J Infect Dis. 2022 May 18. pii: S1201-9712(22)00299.
    PubMed     Abstract available


  500. KIRSCH F, Lindemann AK, Geppert J, Borzekowski D, et al
    Personal Protective Measures During the Coronavirus Pandemic in Germany.
    Int J Infect Dis. 2022 May 18. pii: S1201-9712(22)00297.
    PubMed     Abstract available


  501. EYU P, Elyanu P, Ario AR, Ntono V, et al
    Investigation of Possible Preventable Causes of COVID-19 Deaths in the Kampala Metropolitan Area, Uganda, 2020-2021.
    Int J Infect Dis. 2022 May 17. pii: S1201-9712(22)00296.
    PubMed     Abstract available


  502. GUPTA S, Gupta T, Gupt N
    Global Respiratory Virus Surveillance: Strengths, Gaps and Way Forward.
    Int J Infect Dis. 2022 May 15. pii: S1201-9712(22)00294.
    PubMed     Abstract available


  503. XUE L, Jing S, Zhang K, Milne R, et al
    Infectivity versus fatality of SARS-CoV-2 mutations and influenza.
    Int J Infect Dis. 2022 May 15. pii: S1201-9712(22)00295.
    PubMed     Abstract available


  504. OKOTURO E, Amure M
    SARS-CoV-2 saliva testing using reverse transcriptase - polymerase chain reaction (RT-PCR): A Systematic Review.
    Int J Infect Dis. 2022 May 13. pii: S1201-9712(22)00272.
    PubMed     Abstract available


  505. NISHIURA H, Jung SM, Hayashi K
    High population burden of Omicron variant (B.1.1.529) is associated with the emergence of severe hepatitis of unknown etiology in children.
    Int J Infect Dis. 2022 May 13. pii: S1201-9712(22)00290.
    PubMed     Abstract available


  506. MARCO R, Angelo DV
    Commentary to the paper: Association of smoking and severity of covid-19 infection among 5889 patients in malaysia: a multi-centre observational study, by Ismail N, Hassan N, Hamid MHNA, Yusoff UN, Khamal NR, Omar MA, et al. published in Int J Infect
    Int J Infect Dis. 2022 May 12. pii: S1201-9712(22)00284.
    PubMed    


  507. INGHELS M, Kane R, Lall P, Nelson D, et al
    Ethnicity and risk of SARS-CoV-2 infection among the healthcare workforce: Results of a retrospective cohort study in rural United Kingdom.
    Int J Infect Dis. 2022 May 12. pii: S1201-9712(22)00281.
    PubMed     Abstract available


  508. YILDIZ Y, Ozger HS, Senol E, Karakus R, et al
    Evaluation of long term antibody kinetics in healthcare workers (HCWs) vaccinated with inactivated COVID-19 vero cell vaccine (CoronaVac), a propensity score matched observational study: Antibody kinetics in HCWs after CoronaVac vaccination.
    Int J Infect Dis. 2022 May 11. pii: S1201-9712(22)00271.
    PubMed     Abstract available


  509. OLIVEIRA-SILVA J, Reis T, Lopes C, Batista-Silva R, et al
    Long term serological SARS-CoV-2 IgG kinetics following mRNA COVID-19 vaccine: real-world data from a large cohort of healthcare workers.
    Int J Infect Dis. 2022 May 11. pii: S1201-9712(22)00289.
    PubMed     Abstract available


  510. CHEN F, Tian Y, Zhang L, Shi Y, et al
    The Role of Children in Household Transmission of COVID-19: A Systematic Review and Meta-Analysis.
    Int J Infect Dis. 2022 May 10. pii: S1201-9712(22)00283.
    PubMed     Abstract available


  511. ICHIKAWA T, Torii S, Suzuki H, Takada A, et al
    Mutations in the non-structural proteins of SARS-CoV-2 may contribute to adverse clinical outcome in COVID-19 patients.
    Int J Infect Dis. 2022 May 10. pii: S1201-9712(22)00275.
    PubMed     Abstract available


  512. BALUSHI AA, Ajmi AA, Sinani QA, Menon V, et al
    COVID-19 Associated Mucormycosis: Opportunistic Fugal Infection. A case series and review.
    Int J Infect Dis. 2022 May 6. pii: S1201-9712(22)00267.
    PubMed     Abstract available


  513. COLANERI M, Amarasinghe N, Rezzonico L, Pieri TC, et al
    Early Remdesivir to prevent severe COVID-19 in solid organ transplant recipients: a real-life study from Northern Italy.
    Int J Infect Dis. 2022 May 6. pii: S1201-9712(22)00263.
    PubMed     Abstract available


    April 2022
  514. KAMEGAI K, Iwamoto N, Togano T, Maeda K, et al
    A Fatal Breakthrough Coronavirus Disease 2019 Case Following Bendamustine-Rituximab Therapy.
    Int J Infect Dis. 2022 Apr 29. pii: S1201-9712(22)00258.
    PubMed     Abstract available


  515. YOSHIMURA Y, Sasaki H, Miyata N, Miyazaki K, et al
    An autopsy case of COVID-19-like acute respiratory distress syndrome after mRNA-1273 SARS-CoV-2 vaccination.
    Int J Infect Dis. 2022 Apr 29. pii: S1201-9712(22)00257.
    PubMed     Abstract available


  516. HUSIN M, Tok PSK, Suah JL, Thevananthan T, et al
    Real-world effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection among adolescents (12 to 17-year-olds) in Malaysia.
    Int J Infect Dis. 2022 Apr 29. pii: S1201-9712(22)00251.
    PubMed     Abstract available


  517. BHAKTA S, Sanghavi DK, Johnson PW, Kunze KL, et al
    Clinical and Laboratory Profiles of SARS-CoV-2 Delta Variant Compared to Pre-Delta Variants.
    Int J Infect Dis. 2022 Apr 26. pii: S1201-9712(22)00252.
    PubMed     Abstract available


  518. PAROLINA L, Pshenichnaya N, Vasilyeva I, Lizinfed I, et al
    Clinical characteristics of COVID-19 in TB patients and factors associated with the disease severity.
    Int J Infect Dis. 2022 Apr 25. pii: S1201-9712(22)00232.
    PubMed     Abstract available


  519. LI J, Liu B, Tang X, Wu Z, et al
    Development of a smartphone based quantum-dot lateral flow immunoassay strip for ultrasensitive detection of anti-SARS-CoV-2 IgG and neutralizing antibodies.
    Int J Infect Dis. 2022 Apr 25. pii: S1201-9712(22)00235.
    PubMed     Abstract available


  520. MURILLO-ZAMORA E, Trujillo X, Huerta M, Rios-Silva M, et al
    COVID-19 vaccines provide better protection against related pneumonia than previous symptomatic infection.
    Int J Infect Dis. 2022 Apr 24. pii: S1201-9712(22)00245.
    PubMed     Abstract available


  521. XIA Y, Ma H, Buckeridge DL, Brisson M, et al
    Mortality trends and lengths of stay among hospitalized COVID-19 patients in Ontario and Quebec (Canada): a population-based cohort study of the first three epidemic waves.
    Int J Infect Dis. 2022 Apr 24. pii: S1201-9712(22)00246.
    PubMed     Abstract available


  522. STEIN M, Cohen H, Nemet I, Atari N, et al
    Human Metapneumovirus prevalence during 2019-2021 in Israel is influence by the COVID-19 pandemic.
    Int J Infect Dis. 2022 Apr 23. pii: S1201-9712(22)00241.
    PubMed     Abstract available


  523. TORRES JP, Saure D, Basso LJ, Zuniga M, et al
    SARS-COV-2 IgG positivity in vaccinated and non-vaccinated Chilean children: a national cross-sectional study in Schools.
    Int J Infect Dis. 2022 Apr 23. pii: S1201-9712(22)00238.
    PubMed    


  524. LAI MY, Bukhari FDM, Zulkefli NZ, Ismail I, et al
    Colorimetric detection of SARS-CoV-2 by uracil-DNA glycosylase (UDG) reverse transcription loop-mediated isothermal amplification (RT-LAMP).
    Int J Infect Dis. 2022 Apr 23. pii: S1201-9712(22)00239.
    PubMed     Abstract available


  525. MAMETJA S, Dessie ZG, Matoti L, Semenya M, et al
    Clinical Management of COVID-19 in Hospitals and the Community: A Snapshot from a Medical Insurance Database in South Africa.
    Int J Infect Dis. 2022 Apr 22. pii: S1201-9712(22)00231.
    PubMed     Abstract available


  526. HUNG DT, Ghula S, Aziz JMA, Makram AM, et al
    The efficacy and adverse effects of favipiravir on COVID-19 patients: a systematic review and meta-analysis of published clinical trials and observational studies.
    Int J Infect Dis. 2022 Apr 22. pii: S1201-9712(22)00237.
    PubMed     Abstract available


  527. PETRONE L, Picchianti-Diamanti A, Sebastiani GD, Aiello A, et al
    Humoral and cellular responses to spike of delta SARS-CoV-2 variant in vaccinated patients with Immune Mediated Inflammatory Diseases.
    Int J Infect Dis. 2022 Apr 21. pii: S1201-9712(22)00229.
    PubMed     Abstract available


  528. LIU Y, Yu Y, Zhao Y, He D, et al
    Reduction in the infection fatality rate of Omicron variant compared to previous variants in South Africa.
    Int J Infect Dis. 2022 Apr 21. pii: S1201-9712(22)00228.
    PubMed     Abstract available


  529. KOUTALOS AA, Stefanou N, Malizos KN
    Post-acute sequelae of SARS-CoV-2 infection. Osteonecrosis must not be overlooked.
    Int J Infect Dis. 2022 Apr 21. pii: S1201-9712(22)00226.
    PubMed     Abstract available


  530. JAHAN N, Brahma A, Kumar MS, Bagepally BS, et al
    Corrigendum to 'Seroprevalence of IgG antibodies against SARS-CoV-2 in India, March 2020-August 2021: a systematic review and meta-analysis' [International Journal of Infectious Diseases, Volume 116 (2022) P59-67].
    Int J Infect Dis. 2022;119:119.
    PubMed    


  531. VOO TC, Ballantyne A, Jenn NC, Cowling BJ, et al
    Public acceptability of COVID-19 control measures in Singapore, Hong Kong, and Malaysia: A cross-sectional survey.
    Int J Infect Dis. 2022 Apr 14. pii: S1201-9712(22)00222.
    PubMed     Abstract available


  532. TEGELER CM, Bilich T, Maringer Y, Salih HR, et al
    Prevalence of COVID-19-associated symptoms during acute infection in relation to SARS-CoV-2-directed humoral and cellular immune responses in a mild-diseased convalescent cohort.
    Int J Infect Dis. 2022 Apr 14. pii: S1201-9712(22)00219.
    PubMed     Abstract available


  533. RAMIREZ C, Duron RM
    The Russia-Ukraine war could bring catastrophic public-health challenges beyond COVID-19.
    Int J Infect Dis. 2022 Apr 12. pii: S1201-9712(22)00215.
    PubMed    


  534. TEMBO J, Egbe NF, Maluzi K, Mulonga K, et al
    Evaluation of SARS-CoV-2 diagnostics and risk factors associated with SARS-CoV-2 infection in Zambia.
    Int J Infect Dis. 2022 Apr 12. pii: S1201-9712(22)00216.
    PubMed     Abstract available


  535. LIU K, Wang X, Song G
    Association of epicardial adipose tissue with the severity and adverse clinical outcomes of COVID-19: A meta-analysis.
    Int J Infect Dis. 2022 Apr 11. pii: S1201-9712(22)00212.
    PubMed     Abstract available


  536. JABAL KA, Edelstein M
    Using SARS-CoV-2 anti-S IgG levels as a marker of previous infection: Example from an Israeli Healthcare worker cohort.
    Int J Infect Dis. 2022 Apr 9. pii: S1201-9712(22)00209.
    PubMed     Abstract available


  537. WOLDAY D, de Wit TFR
    Response to Abdelrahman M et al commentary on "Parasites Protect from Severe COVID-19. Myth or Reality?"
    Int J Infect Dis. 2022 Apr 9. pii: S1201-9712(22)00211.
    PubMed    


  538. SOMAN R, Chakraborty S, Joe G
    Posaconazole or Isavuconazole as sole or predominant anti-fungal therapy for COVID-19 associated Mucormycosis. A retrospective observational case series.
    Int J Infect Dis. 2022 Apr 8. pii: S1201-9712(22)00208.
    PubMed    


  539. HAMBRIDGE HL, Kahn R, Onnela JP
    Effect of a Two-Dose vs Three-Dose Vaccine Strategy in Residential Colleges Using an Empirical Proximity Network.
    Int J Infect Dis. 2022 Apr 8. pii: S1201-9712(22)00206.
    PubMed    


  540. DI LEGO V, Sanchez-Romero M, Prskawetz A
    The impact of COVID-19 vaccines on the Case Fatality Rate: The importance of monitoring breakthrough infections.
    Int J Infect Dis. 2022 Apr 6. pii: S1201-9712(22)00197.
    PubMed     Abstract available


  541. HO LL, Gurung S, Mirza I, Nicolas HD, et al
    Impact of the SARS-CoV-2 pandemic on vaccine-preventable disease campaigns.
    Int J Infect Dis. 2022 Apr 6. pii: S1201-9712(22)00204.
    PubMed     Abstract available


  542. WANG X, Wei J, Zhu R, Chen L, et al
    Contribution of CD4+ T cell mediated inflammation to diarrhoea in patients with COVID-19.
    Int J Infect Dis. 2022 Apr 6. pii: S1201-9712(22)00201.
    PubMed     Abstract available


  543. MEDHAT R, El Lababidi R, Abdelsalam M, Nusair A, et al
    Varicella Zoster Virus (VZV) Meningitis in an Immunocompetent Adult following BNT162b2 mRNA COVID-19 Vaccination: A Case Report.
    Int J Infect Dis. 2022 Apr 6. pii: S1201-9712(22)00200.
    PubMed     Abstract available


    March 2022
  544. BURANASAKDA M, Kotruchin P, Phanthachai K, Mootsikapun P, et al
    Varicella zoster meningitis following COVID-19 vaccination: a report of two cases.
    Int J Infect Dis. 2022 Mar 30. pii: S1201-9712(22)00192.
    PubMed     Abstract available


  545. KLOPFENSTEIN T, Tipirdamaz C, Gendrin V, Osman M, et al
    Third of patients have gustatory dysfunction 9 months after SARS-CoV-2 infection: the ANOSVID study.
    Int J Infect Dis. 2022 Mar 29. pii: S1201-9712(22)00193.
    PubMed    


  546. JEGERLEHNER S, Suter-Riniker F, Jent P, Bittel P, et al
    Diagnostic accuracy of SARS-CoV-2 saliva antigen testing in a real-life clinical setting.
    Int J Infect Dis. 2022 Mar 29. pii: S1201-9712(22)00176.
    PubMed     Abstract available


  547. GHOSH A, Walia S, Rattan R, Kanampalliwar A, et al
    Genomic profiles of vaccine breakthrough SARS-CoV-2 strains from Odisha, India.
    Int J Infect Dis. 2022 Mar 28. pii: S1201-9712(22)00181.
    PubMed    


  548. ARKELL P, Gusmao C, Sheridan SL, Tanesi MY, et al
    Serological surveillance of healthcare workers to evaluate natural infection- and vaccine-derived immunity to SARS-CoV-2 during an outbreak in Dili, Timor-Leste.
    Int J Infect Dis. 2022 Mar 28. pii: S1201-9712(22)00183.
    PubMed     Abstract available


  549. JACKSON I, Jaradeh H, Aurit S, Aldamen A, et al
    Role of procalcitonin as a predictor of clinical outcomes in hospitalized patients with COVID-19.
    Int J Infect Dis. 2022 Mar 28. pii: S1201-9712(22)00179.
    PubMed     Abstract available


  550. ABU-ODAH H, Su JJ, Musa SS
    Unwillingness or reluctance of Palestinians to get COVID-19 vaccine: the reasons behind it and how to persuade them.
    Int J Infect Dis. 2022 Mar 25. pii: S1201-9712(22)00178.
    PubMed     Abstract available


  551. CHANDA-KAPATA P, Ntoumi F, Kapata N, Lungu P, et al
    Tuberculosis, HIV/AIDS and Malaria Health Services in sub-Saharan Africa - A Situation Analysis of the Disruptions and Impact of the COVID-19 Pandemic.
    Int J Infect Dis. 2022 Mar 24. pii: S1201-9712(22)00173.
    PubMed     Abstract available


  552. KIM AY, Woo W, Yon DK, Lee SW, et al
    Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A Systematic Review and Meta-Analysis.
    Int J Infect Dis. 2022 Mar 23. pii: S1201-9712(22)00171.
    PubMed     Abstract available


  553. LI R, Liu H, Fairley CK, Zou Z, et al
    Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States.
    Int J Infect Dis. 2022 Mar 22. pii: S1201-9712(22)00168.
    PubMed     Abstract available


  554. SUAH JL, Husin M, Keng PS, Hwa B, et al
    Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study.
    Int J Infect Dis. 2022 Mar 21. pii: S1201-9712(22)00167.
    PubMed     Abstract available


  555. GUO Q, Wang J, Estill J, Lan H, et al
    Risk of COVID-19 Transmission Aboard Aircraft: An Epidemiological Analysis Based on the National Health Information Platform.
    Int J Infect Dis. 2022 Mar 21. pii: S1201-9712(22)00163.
    PubMed     Abstract available


  556. MAKRAM AM, Alied M, Khan ZA, Huy NT, et al
    Parasites Protect from Severe COVID-19. Myth or Reality?
    Int J Infect Dis. 2022 Mar 21. pii: S1201-9712(22)00164.
    PubMed    


  557. JEREMIAH C, Petersen E, Nantanda R, Mungai BN, et al
    The WHO Global Tuberculosis 2021 Report - not so good news and turning the tide back to End TB.
    Int J Infect Dis. 2022 Mar 20. pii: S1201-9712(22)00149.
    PubMed     Abstract available


  558. SHANAUBE K, Schaap A, Klinkenberg E, Floyd S, et al
    SARS-CoV-2 seroprevalence and associated risk factors in peri-urban Zambia: a population-based study.
    Int J Infect Dis. 2022 Mar 16. pii: S1201-9712(22)00158.
    PubMed    


  559. INADA M, Ishikane M, Terada M, Matsunaga A, et al
    Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection.
    Int J Infect Dis. 2022 Mar 16. pii: S1201-9712(22)00155.
    PubMed     Abstract available


  560. ONO A, Koizumi R, Tsuzuki S, Asai Y, et al
    Antimicrobial Use Fell Substantially in Japan in 2020-The COVID-19 Pandemic May Have Played a Role.
    Int J Infect Dis. 2022 Mar 16. pii: S1201-9712(22)00157.
    PubMed     Abstract available


  561. ELEC F, Magnusson J, Elec A, Muntean A, et al
    COVID-19 AND KIDNEY TRANSPLANTATION: THE IMPACT OF REMDESIVIR ON RENAL FUNCTION AND OUTCOME- A RETROSPECTIVE COHORT STUDY.
    Int J Infect Dis. 2022 Mar 14. pii: S1201-9712(22)00151.
    PubMed     Abstract available


  562. NTOUMI F, Petersen E, Mwaba P, Aklillu E, et al
    Blue Skies research is essential for ending the Tuberculosis pandemic and advancing a personalized medicine approach for holistic management of Respiratory Tract infections.: Invited viewpoint: IJID World TB Day series 2022.
    Int J Infect Dis. 2022 Mar 14. pii: S1201-9712(22)00150.
    PubMed     Abstract available


  563. O'KELLY B, Vidal L, Avramovic G, Broughan J, et al
    Assessing the impact of COVID-19 at 1 year using the SF-12 questionnaire: Data from the Anticipate longitudinal cohort study.
    Int J Infect Dis. 2022 Mar 14. pii: S1201-9712(22)00152.
    PubMed     Abstract available


  564. MATTIUZZI C, Henry BM, Lippi G
    COVID-19 vaccination and SARS-CoV-2 Omicron (B.1.1.529) variant: a light at the end of the tunnel?
    Int J Infect Dis. 2022 Mar 9. pii: S1201-9712(22)00146.
    PubMed     Abstract available


  565. LEE DS, Kim JW, Lee KL, Jung YJ, et al
    Adverse events following coronavirus disease 2019 vaccination in South Korea between February 28 and August 21, 2021: A nationwide observational study.
    Int J Infect Dis. 2022 Mar 8. pii: S1201-9712(22)00145.
    PubMed     Abstract available


  566. GLINERT I, Ben-Shmuel A, Szwartcwort-Cohen M, Beth-Din A, et al
    Revisiting SARS-CoV-2 environmental contamination by COVID-19 patients: The Omicron variant does not differ from previous strains.
    Int J Infect Dis. 2022 Mar 4. pii: S1201-9712(22)00139.
    PubMed     Abstract available


  567. LIU ZG, Li XY
    Interpretation of Discrepancies between Cities in the Transmission of COVID-19: Evidence from China in the First Weeks of the Pandemic: Interpreting the Discrepancies of COVID-19 Transmission.
    Int J Infect Dis. 2022 Mar 4. pii: S1201-9712(22)00142.
    PubMed     Abstract available


  568. MORENO-GARCIA E, Puerta-Alcalde P, Letona L, Meira F, et al
    Bacterial co-infection at hospital admission in patients with COVID-19.
    Int J Infect Dis. 2022 Mar 4. pii: S1201-9712(22)00143.
    PubMed     Abstract available


  569. ADRIEN CSK, Alexandre C, Marie M, Cedric J, et al
    Number of initial symptoms is more related to long COVID-19 than acute severity of infection: a prospective cohort of hospitalized patients.
    Int J Infect Dis. 2022 Mar 4. pii: S1201-9712(22)00141.
    PubMed    


  570. RODRIGUEZ GD, Wu Y, Karnik K, Ruddy S, et al
    Implementation of a Collaborated Antimicrobial Stewardship Program and Outpatient Parenteral Antimicrobial Therapy (OPAT) Unit-driven Monoclonal Antibody Therapy Program for COVID-19 at a NYC Hospital.
    Int J Infect Dis. 2022 Mar 3. pii: S1201-9712(22)00137.
    PubMed     Abstract available


  571. ASSAL HH, Abdelrahman S, Abdelbasset MA, Abdelaziz M, et al
    Presepsin as a Novel Biomarker in predicting Inhospital Mortality in COVID-19 Pneumonia Patients.
    Int J Infect Dis. 2022 Mar 3. pii: S1201-9712(22)00136.
    PubMed     Abstract available


  572. PETERSEN E, Al-Abri S, Chakaya J, Goletti D, et al
    World TB Day 2022: Revamping and Reshaping Global TB Control Programs by Advancing Lessons learnt from the COVID-19 pandemic.
    Int J Infect Dis. 2022 Mar 3. pii: S1201-9712(22)00138.
    PubMed    


  573. MUSSO N, Maugeri JG, Bongiorno D, Stracquadanio S, et al
    SARS-CoV-2's high rate of genetic mutation under immune selective pressure: from oropharyngeal B.1.1.7 to intrapulmonary B.1.533 in a post-vaccine patient.
    Int J Infect Dis. 2022 Mar 2. pii: S1201-9712(22)00123.
    PubMed     Abstract available


  574. LAYER E, Hoehl S, Ciesek S, Widera M, et al
    SARS-CoV-2 screening strategies for returning international travellers: Evaluation of a rapid antigen test approach.
    Int J Infect Dis. 2022 Mar 2. pii: S1201-9712(22)00121.
    PubMed     Abstract available


  575. EFIMENKO I, Nackeeran S, Jabori S, Zamora JAG, et al
    REMOVED: Treatment with Ivermectin Is Associated with Decreased Mortality in COVID-19 Patients: Analysis of a National Federated Database.
    Int J Infect Dis. 2022;116S:S40.
    PubMed     Abstract available


    February 2022
  576. HUSSEY H, Davies MA, Heekes A, Williamson C, et al
    Assessing the clinical severity of the Omicron variant in the Western Cape Province, South Africa, using the diagnostic PCR proxy marker of RdRp target delay to distinguish between Omicron and Delta infections - a survival analysis.
    Int J Infect Dis. 2022 Feb 27. pii: S1201-9712(22)00129.
    PubMed     Abstract available


  577. SHURRAB FM, Younes N, Al-Sadeq DW, Liu N, et al
    Performance evaluation of novel fluorescent-based lateral immune flow assay (LIFA) for rapid detection and quantification of total anti-SARS-CoV-2 S-RBD binding antibodies in infected individuals.
    Int J Infect Dis. 2022 Feb 26. pii: S1201-9712(22)00130.
    PubMed     Abstract available


  578. ROUAMBA T, Ouedraogo E, Barry H, Yameogo NV, et al
    Assessment of Recovery Time, Worsening and Death, among COVID-19 inpatients and outpatients, under treatment with Hydroxychloroquine or Chloroquine plus Azithromycin Combination in Burkina Faso.
    Int J Infect Dis. 2022 Feb 25. pii: S1201-9712(22)00111.
    PubMed     Abstract available


  579. ALBAHRANI S, Ahmadi NA, Hamdan S, Elsheikh N, et al
    Clinical Presentation and Outcome of hospitalized patients with COVID-19 in the first and second wave in Saudi Arabia.
    Int J Infect Dis. 2022 Feb 25. pii: S1201-9712(22)00127.
    PubMed     Abstract available


  580. THEOHARIDES TC, Guerra L, Patel K
    Successful Treatment of a Severe COVID-19 Patient Using an Integrated Approach Addressing Mast Cells and Their Mediators.
    Int J Infect Dis. 2022 Feb 25. pii: S1201-9712(22)00128.
    PubMed     Abstract available


  581. HIRATA M, Fukuchi T, Sugawara H
    Trajectory of SARS-CoV-2 anti-S IgG levels following transfusion and a third dose of BNT162b2 vaccine in a patient with massive postoperative bleeding: A case report.
    Int J Infect Dis. 2022 Feb 24. pii: S1201-9712(22)00122.
    PubMed     Abstract available


  582. XIE M, Dong N, Zhang X, He D, et al
    Exported Cases were Infected on the Way: A Conjecture Derived from Analysis on Hong Kong Monthly Exported Covid-19 Cases.
    Int J Infect Dis. 2022 Feb 23. pii: S1201-9712(22)00102.
    PubMed    


  583. ROSENTHAL VD, Myatra SN, Divatia JV, Biswas S, et al
    The impact of COVID-19 on healthcare-associated infections in intensive care units in low and middle income countries: International Nosocomial Infection Control Consortium (INICC) findings.
    Int J Infect Dis. 2022 Feb 23. pii: S1201-9712(22)00120.
    PubMed     Abstract available


  584. LITCHFIELD M, Brookes P, Ojrzynska A, Kavi J, et al
    Comparison of the clinical sensitivity and specificity of two commercial RNA SARS-CoV-2 assays.
    Int J Infect Dis. 2022 Feb 22. pii: S1201-9712(22)00109.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO COVID-19 is free of charge.